Survodutide Clinical Protocol

Clinical-education protocol for survodutide (Boehringer Ingelheim development code BI 456906; co-developed with Zealand Pharma), a GLP-1 / glucagon dual receptor agonist in active Phase 3 development under the SYNCHRONIZE obesity portfolio and LIVERAGE MASH portfolio. This protocol prepares clinicians for survodutide’s anticipated availability based on Phase 3 readout data; current prescribing requires off-label use of investigational supply OR enrollment in active clinical trials. Survodutide is pre-FDA-approval-for-marketing-claims as of 2026-05-13; SYNCHRONIZE-1 sponsor topline (April 2026, Boehringer Ingelheim press release) reported approximately 16.6% body-weight reduction at 6.0 mg at 76 weeks; peer-reviewed primary publication PMID assignment is pending. FDA submission is anticipated post-Phase 3 program completion per Boehringer Ingelheim investor communications; FDA Breakthrough Therapy designation for MASH has been granted (regulatory-procedural status under FDCA §506(a); does not constitute approval).

FDA-approved for marketing claims — load-bearing precision (Editorial Framework §1.2.1; Pattern AA.marketing-claims). When this protocol references survodutide’s regulatory state as “pre-FDA-approval,” the load-bearing phrase is “pre-FDA-approval-for-marketing-claims.” FDA approval is approval-for-marketing-claims for specific named indications. When this protocol references class comparators as “FDA-approved” (semaglutide, tirzepatide, resmetirom), the load-bearing phrase is “FDA-approved for marketing claims for [indication X].” Off-label use of an FDA-approved-for-marketing-claims drug remains use of an FDA-approved drug.

Pattern AA framing throughout. Every regulatory-claim sentence defaults to “investigational,” “Phase 3 readout pending,” “anticipated FDA submission post-Phase 3 program completion,” “FDA Breakthrough Therapy designation (regulatory-procedural status, not approval).” The protocol body never uses “approved” or “FDA-approved” for survodutide itself except in the negative (“pre-FDA-approval-for-marketing-claims”) or when referring explicitly to FDA-approved-for-marketing-claims class comparators (semaglutide, tirzepatide, resmetirom, mazdutide in China per NMPA).

Dual GLP-1R + glucagon-receptor mechanism. Sections 1, 2, 3, 4, 5, 6, 7, 8 are structured to reflect the GLP-1R + GCGR dual-receptor pharmacology — particularly the glucagon-receptor-agonism component, which is mechanism-class-distinct from semaglutide (single GLP-1R), tirzepatide (GLP-1/GIP dual), and the triagonist class (GLP-1/GIP/glucagon). Hepatic GCGR activation is the survodutide-specific mechanism dimension driving the MASH efficacy hypothesis and the survodutide-specific hepatic-transaminase monitoring posture in §3.4 and §5.5.

§10 Pattern Z calibration. Anchor 5 (off-label / extrapolation transparency) is the dominant calibration surface for survodutide today, because the only routes to survodutide use as of 2026-05-13 are (a) enrollment in an active SYNCHRONIZE or LIVERAGE Phase 3 trial, (b) investigational-supply acquisition through research-protocol channels, or (c) compounded preparations from compounding pharmacies operating under pre-approval regulatory conditions distinct from the post-FDA-approval shortage-driven 503A/503B framework that applied to compounded semaglutide and tirzepatide during 2022-2024 shortage periods. Anchor 2 (compounded counseling) operates here under pre-approval-compound adaptation and is reframed in §10.3 as investigational-supply-and-compounded-pre-approval framing, NOT as post-approval 503A/503B shortage-period framing.

Indication scope and patient phenotypes
Selection criteria (inclusion / exclusion / contraindications)
Pre-treatment workup
Initiation protocol
Maintenance protocol
Side-effect management
Plateau and non-response algorithm
Discontinuation and tapering
Combination rules
Patient counseling beats (Pattern Z calibration-anchor-compliant)
Source citations
Clinical decision tree

Appendices

A. Verification gate
B. Pattern discipline summary
C. Self-audit findings

1. Indication scope and patient phenotypes

1.1 Purpose

This protocol prepares clinicians for survodutide’s anticipated availability based on Phase 3 readout data; current prescribing requires off-label use of investigational supply OR enrollment in active clinical trials. Survodutide is NOT FDA-approved as of 2026-05-13. The clinical-education framing provides a Module 5 Protocol Template-structured reference for understanding the GLP-1 / glucagon dual-agonist mechanism class, the anticipated indication scope per the SYNCHRONIZE + LIVERAGE Phase 3 program design, the expected effect-size magnitudes per the published Phase 2 evidence base plus the SYNCHRONIZE-1 sponsor-disclosed topline, and the safety considerations specific to the dual-receptor pharmacology — most particularly the hepatic glucagon-receptor activation pathway that defines the survodutide MASH efficacy hypothesis and the survodutide-specific transaminase-monitoring posture.

Current prescribing reality (2026-05-13). Survodutide is in active Phase 3 with the SYNCHRONIZE obesity portfolio (six trials) and the LIVERAGE MASH portfolio (two trials). The status snapshot:

SYNCHRONIZE-1 (NCT06066515; obesity without T2D; n≈4,734; 76 weeks) reached primary completion 2025-12-02. The Boehringer Ingelheim April 2026 sponsor topline disclosed approximately 16.6% body-weight reduction at the 6.0 mg dose vs placebo; peer-reviewed primary publication PMID assignment is pending as of 2026-05-13.
SYNCHRONIZE-2 (NCT06066528; obesity + T2D), SYNCHRONIZE-MASLD (NCT06309992; obesity + NASH overlap), SYNCHRONIZE-JP (NCT06176365; Japan), and SYNCHRONIZE-CN (NCT06214741; China) reached primary completion in 2025 (between 2025-07-29 and 2025-12-12); peer-reviewed primary publications are pending.
SYNCHRONIZE-CVOT (NCT06077864; cardiovascular outcomes in obesity + established CVD or CKD or ≥2 weight-related complications) is ACTIVE_NOT_RECRUITING with primary completion 2026-05-01; the event-driven cardiovascular outcomes readout is pending.
LIVERAGE (NCT06632444; MASH F2/F3) is RECRUITING with primary completion 2031-12-27.
LIVERAGE-Cirrhosis (NCT06632457; MASH F4 compensated cirrhosis) is RECRUITING with primary completion 2029-06-05 — the first Phase 3 readout planned for any GLP-1 / glucagon dual agonist in compensated cirrhosis, class-comparator-relevant to the Loomba 2023 semaglutide Phase 2 result (PMID 36934740) where the primary fibrosis-improvement endpoint did not reach statistical significance in the F4 cirrhosis population.

FDA Breakthrough Therapy designation for MASH has been granted per Boehringer Ingelheim public disclosures. Pattern AA precision: Breakthrough Therapy designation is a regulatory-procedural status under FDCA §506(a) granting expedited development/review pathway features. It does NOT constitute FDA approval, does NOT constitute FDA endorsement of efficacy or safety claims, and does NOT guarantee subsequent FDA approval. The substantial-evidence threshold for marketing authorization under FDCA §505(d) must still be met through NDA submission and FDA review. FDA submission timing is dependent on Boehringer Ingelheim’s Phase 3 program completion trajectory and is not Boehringer-disclosed as a specific calendar quarter as of 2026-05-13; anticipated regulatory trajectory based on current Phase 3 readout schedule supports FDA submission in 2026-2027 conditional on Phase 3 SYNCHRONIZE readouts (and on the LIVERAGE program for the MASH indication submission, with the F4 cirrhosis readout planned 2029-06).

What this protocol IS. A clinical-education reference for the anticipated survodutide profile, structured against the Module 5 Protocol Template (template post-patch 20e66bd). Clinicians use this protocol to (a) understand the GLP-1 / glucagon dual-agonist mechanism class in the context of FDA-approved-for-marketing-claims comparator classes (semaglutide single-GLP-1R; tirzepatide dual GLP-1/GIP; resmetirom THRb-selective for MASH); (b) prepare for survodutide-specific clinical questions from patients who are tracking the Phase 3 readout schedule, considering investigational-supply or compounded-preparation acquisition, considering enrollment in active SYNCHRONIZE or LIVERAGE trials, or asking about the FDA Breakthrough Therapy designation status; (c) anticipate the protocol-level operational considerations — particularly the hepatic + glucagon-receptor-related monitoring posture from canonical §6.13 and §8.5.5 — that will apply post-approval.

What this protocol IS NOT. It is not a current-prescribing protocol for the general patient population. Current survodutide use is restricted to (a) enrollment in an active SYNCHRONIZE-CVOT, LIVERAGE, LIVERAGE-Cirrhosis, ARROW Phase 2 CKD, or other survodutide trial under the trial protocol’s investigational-supply provision; (b) off-label clinical use of investigational supply where research-protocol acquisition pathways exist and where clinician judgment supports the use under informed-consent standards; (c) clinical-practice access through compounded preparations from compounding pharmacies, with the pre-approval-compound regulatory considerations developed in §10.3. It does not establish a prescribing recommendation for the general clinical population.

Pattern R.1 enforcement at this section: the protocol opens with what survodutide IS (Phase 3 GLP-1 / glucagon dual agonist in active development; mechanism class; anticipated profile per published evidence base including the Phase 2 MASH NEJM publication and the SYNCHRONIZE-1 sponsor topline; FDA Breakthrough Therapy designation for MASH as regulatory-procedural status) and with the clinical-education framing — not with regulatory deficits or with what survodutide is not. Pattern AA enforcement: every regulatory claim in this section carries the pre-approval-state qualification and the Breakthrough-Therapy-designation-precision qualification.

Pattern R.2 enforcement: the indication scope is locked at the section-architecture-design step. The anticipated indication scope per the SYNCHRONIZE + LIVERAGE program design is: chronic weight management (CWM) in obesity / overweight without T2D (SYNCHRONIZE-1); CWM in obesity + T2D (SYNCHRONIZE-2); cardiovascular safety and outcomes in obesity + established CVD/CKD/≥2 weight-related complications (SYNCHRONIZE-CVOT); CWM in obesity + NASH overlap (SYNCHRONIZE-MASLD); regional CWM (SYNCHRONIZE-JP, SYNCHRONIZE-CN); MASH F2/F3 (LIVERAGE); MASH F4 compensated cirrhosis (LIVERAGE-Cirrhosis); and the investigator-initiated CKD direction (ARROW Phase 2, University Medical Center Groningen). This scope is locked here; downstream sections are read through this scope with explicit Pattern AA qualification that all indications are anticipated-pending-Phase-3-readouts.

1.2 Anticipated indication categories (pending Phase 3 readouts)

A survodutide-protocol indication category framework follows the Module 5 Protocol Template’s eight indication categories, with every category explicitly framed under the pre-FDA-approval anticipated-indication discipline. Pattern AA enforcement: every category is stated with its anticipated-status qualification (Phase 3 readout pending, or sponsor-disclosed topline pending peer-reviewed publication, or Phase 2 peer-reviewed published with Phase 3 readout pending), with anchor to the specific SYNCHRONIZE or LIVERAGE trial and primary endpoint.

The anticipated survodutide indication categories per the SYNCHRONIZE + LIVERAGE program design:

Chronic weight management (CWM) — obesity / overweight without T2D (anticipated). Anchored to SYNCHRONIZE-1 (NCT06066515; n≈4,734; 76 weeks; COMPLETED 2025-12-02). Effect-size anchor: Boehringer Ingelheim April 2026 sponsor topline disclosed approximately 16.6% body-weight reduction at the 6.0 mg dose vs placebo at 76 weeks; peer-reviewed primary publication PMID assignment is pending as of 2026-05-13 (Pattern AA framing — press-release-source topline disclosure, not peer-reviewed Phase 3 results). Comparator-class context: STEP-1 semaglutide 2.4 mg achieved approximately −14.9% at 68 weeks in non-diabetic obesity (Wilding 2021); SURMOUNT-1 tirzepatide 15 mg achieved approximately −20.9% (treatment-regimen estimand, PRIMARY ITT) / approximately −22.5% (efficacy estimand sub-analysis) at 72 weeks (Jastreboff 2022 PMID 35658024); SURMOUNT-5 head-to-head at week 72 in obesity showed tirzepatide −20.2% vs semaglutide −13.7% (Aronne 2025). Pattern V.metric-axis precision: the SYNCHRONIZE-1 16.6% figure is the sponsor-topline percentage at the 6.0 mg dose vs placebo at 76 weeks; the per-arm vs between-group estimand structure is anticipated to be characterized in the peer-reviewed primary publication. Peer-reviewed Phase 2 anchor: le Roux CW et al. Lancet Diabetes Endocrinol 2024 (PMID 38330987; NCT04667377; n=387; 46 weeks): −14.9% at 4.8 mg vs −2.8% placebo in non-diabetic obesity.
Type 2 diabetes mellitus (T2D) — glycemic control and chronic weight management with T2D (anticipated). Anchored to SYNCHRONIZE-2 (NCT06066528; n≈870; 76 weeks; obesity + T2D; COMPLETED 2025-12-12; peer-reviewed primary publication pending). Effect-size anchor (peer-reviewed Phase 2): Blüher M et al. Diabetologia 2024 (PMID 38095657; n=413; 16 weeks; T2D dose-response across multiple dose arms vs placebo, with an exploratory open-label semaglutide 1.0 mg reference arm). Pattern AA-precise framing: the survodutide-vs-semaglutide reference comparison in the Blüher 2024 trial is exploratory, NOT a head-to-head equivalence or superiority test — the trial was not designed or powered to compare survodutide and semaglutide head-to-head. A Published Erratum (PMID 38349400) exists to PMID 38095657; the primary citation for evidence claims is PMID 38095657.
Cardiovascular outcomes in obesity + established CVD or CKD or ≥2 weight-related complications (anticipated). Anchored to SYNCHRONIZE-CVOT (NCT06077864; n per registry; event-driven Phase 3; ACTIVE_NOT_RECRUITING; primary completion 2026-05-01). The event-driven MACE composite primary endpoint readout is pending; the trial enrolled participants with overweight or obesity plus established cardiovascular disease, or chronic kidney disease, or at least two weight-related complications or risk factors for CVD. Effect-size anchors are Phase 3 readout-pending; class-comparator framing (Pattern AA-precise comparator caveat per §10.5) is SELECT semaglutide three-point MACE HR approximately 0.80 (95% CI 0.72-0.90) in obesity without diabetes (Lincoff 2023 NEJM PMID 37952131) and SURMOUNT-MMO tirzepatide CV outcomes in active Phase 3 program.
Chronic weight management — obesity + NASH overlap (anticipated). Anchored to SYNCHRONIZE-MASLD (NCT06309992; 48 weeks; obesity + presumed/confirmed NASH; COMPLETED 2025-10-09; peer-reviewed primary publication pending). This trial captures the clinically common overlap population (obesity + NASH co-morbidity) distinct from the dedicated MASH F2/F3 LIVERAGE design which enrolls based on histology-confirmed fibrosis stage.
Metabolic dysfunction-associated steatohepatitis (MASH) F2/F3 — anticipated MASH-specific indication. Anchored to LIVERAGE (NCT06632444; Phase 3 RCT in non-cirrhotic MASH/NASH with F2-F3 fibrosis; RECRUITING; primary completion 2031-12-27). Effect-size anchor (peer-reviewed Phase 2): Sanyal AJ et al. NEJM 2024 Jul 25 (PMID 38847460; survodutide Phase 2 MASH RCT, NCT04771273; n=295) — 62% MASH resolution at the 6.0 mg dose vs 14% placebo at 48 weeks, with dose-responsive fibrosis improvement of at least one stage without worsening MASH (64% at 6.0 mg vs 26% placebo). Pattern AB.1 disambiguation: PMID 38847460 is the survodutide Phase 2 MASH publication. PMID 38856224 is the same-day NEJM publication of tirzepatide SYNERGY-NASH Phase 2 MASH (Loomba R et al.; n=190; 62% MASH resolution at 15 mg vs 10% placebo at 52 weeks). The two NEJM papers published on the same day (2024-07-25) require careful attribution at every citation; this protocol’s §11 Bibliography enforces the Pattern AB.1 inversion-prevention check. The LIVERAGE Phase 3 trial design reflects the Phase 2 dose-response findings and the FDA Breakthrough Therapy designation pathway.
MASH F4 compensated cirrhosis — anticipated MASH-cirrhosis-specific indication. Anchored to LIVERAGE-Cirrhosis (NCT06632457; Phase 3 RCT in compensated NASH/MASH cirrhosis F4; RECRUITING; primary completion 2029-06-05). This is the load-bearing trial for the survodutide MASH F4 evidence base — and the first Phase 3 readout planned for any GLP-1 / glucagon dual agonist in compensated cirrhosis. Class-comparator context: Loomba R et al. Lancet Gastroenterol Hepatol 2023 (PMID 36934740; n=71; 48 weeks; Phase 2 RCT of semaglutide 2.4 mg weekly in NASH-related cirrhosis) reported that the primary endpoint — improvement in liver fibrosis by ≥1 stage without worsening of NASH at week 48 — did not reach statistical significance in this F4 cirrhosis population. Pattern V critical: characterize the Loomba 2023 F4 finding precisely as “Phase 2 RCT with primary fibrosis-improvement endpoint not statistically significant in the cirrhosis population” — NOT as “directional finding,” “trend toward improvement,” or “directional protective signal.” The phrasings that inflate a non-significant Phase 2 endpoint result are Pattern V-violating. Cirrhosis-population PK for survodutide is characterized in Lawitz EJ et al. J Hepatol 2024 (PMID 38857788; NCT05296733).
Cardiovascular outcomes in CWM — distinct from #3. SYNCHRONIZE-CVOT (above) is the cardiovascular outcomes trial; this category is encompassed within #3 and is not a separate indication category.
Regional CWM (Japan, China). Anchored to SYNCHRONIZE-JP (NCT06176365; Japan obesity; 76 weeks; COMPLETED 2025-12-03) and SYNCHRONIZE-CN (NCT06214741; China obesity; 76 weeks; COMPLETED 2025-07-29). Both reached primary completion in 2025; peer-reviewed primary publications pending. These regional Phase 3 trials address population-specific clinical considerations including ethnic-genetic factors influencing PK and PD, regional dietary and metabolic patterns relevant to obesity treatment, and regional regulatory submission strategies. Anticipated FDA-submission indication scope likely does not directly include the regional trials, but the regional data inform pooled efficacy and safety characterization.

Investigator-initiated additional indication direction — chronic kidney disease (anticipated, very early). Anchored to ARROW Phase 2 (NCT07206290; investigator-initiated by University Medical Center Groningen; NOT_YET_RECRUITING; primary completion 2027-11-30). Albuminuria reduction primary endpoint — the first dedicated investigator-initiated GLP-1 / glucagon dual-agonist renal-outcomes trial. Effect-size anchors are research-state; class-comparator context is FLOW semaglutide in T2D + CKD.

Cross-trial enumeration consistency (Pattern W). The survodutide Phase 3 program comprises eight trials: six SYNCHRONIZE trials (-1, -2, -CVOT, -MASLD, -JP, -CN) and two LIVERAGE trials (F2/F3, Cirrhosis F4). The investigator-initiated ARROW Phase 2 trial is a separate research direction. This enumeration is locked here in §1.2 and is reconciled across §3 workup, §4 initiation, §5 maintenance, §10 counseling, §11 citations, and §12 decision tree.

Pattern AA precision applied to §1.2. Every anticipated indication category is stated with the appropriate qualification: peer-reviewed (Phase 2 MASH Sanyal 2024; Phase 2 obesity le Roux 2024; Phase 2 T2D Blüher 2024; Phase 1 cirrhosis-population PK Lawitz 2024) vs sponsor-disclosure-pending-peer-reviewed-publication (SYNCHRONIZE-1 16.6% topline, April 2026 Boehringer Ingelheim press release) vs Phase 3 readout-pending (SYNCHRONIZE-2, -CVOT, -MASLD, -JP, -CN; LIVERAGE F2/F3; LIVERAGE-Cirrhosis F4). FDA Breakthrough Therapy designation for MASH is stated as a regulatory-procedural status under FDCA §506(a), not as approval or approval-equivalent.

1.3 Phenotype-targeting taxonomy

The Module 5 phenotype taxonomy from M5.1 Pathophysiology — Patient Questions applies to survodutide as it does to other Module 5 protocols, with survodutide-specific phenotype-targeting considerations arising from the dual GLP-1R + GCGR mechanism class. The taxonomy dimensions:

Metabolic phenotype. Insulin-resistant vs insulin-sensitive obesity; hyperinsulinemic vs normoinsulinemic; hepatic-IR-dominant vs adipose-IR-dominant vs muscle-IR-dominant. Survodutide-specific consideration: the hepatic GCGR-mediated fatty-acid β-oxidation mechanism (canonical §2.4) is mechanism-class-distinct from single-GLP-1R agonists and GLP-1/GIP dual agonists. The hepatic-IR-dominant phenotype with ectopic-fat-positive distribution (liver steatosis) is the candidate phenotype subgroup where the GCGR component may provide differential effect-magnitude beyond the GLP-1R-mediated weight-loss-mediated benefit; this is research-state-incomplete pending the LIVERAGE Phase 3 and Phase 2 hepatic-fat-reduction mechanism work (NCT06745284 energy-expenditure trial; NCT05202353 receptor-occupancy comparison vs semaglutide).
Adiposity distribution. Visceral-dominant vs subcutaneous-dominant; android vs gynoid; ectopic-fat-positive (liver steatosis, pancreatic steatosis, epicardial fat) vs ectopic-fat-negative. Survodutide-specific consideration: the Phase 2 MASH trial (Sanyal 2024 PMID 38847460) hepatic-fat-reduction and MASH-resolution magnitude at 6.0 mg / 48 weeks (62% resolution vs 14% placebo) is one of the largest histopathology-endpoint magnitudes observed for any pharmacotherapy class in the MASH context as of 2026-05-13; phenotype-targeting consideration favors survodutide for the ectopic-fat-positive hepatic-fibrosis-positive phenotype, pending LIVERAGE Phase 3 confirmation.
Appetite phenotype. Hyperphagia-dominant vs slow-satiety-dominant vs hedonic-eating-dominant vs nocturnal-eating-dominant. GLP-1R-mediated central appetite suppression is shared across the GLP-1 RA class and underlies the survodutide appetite-modulation component. Survodutide-specific phenotype-targeting differential within the appetite-phenotype taxonomy is research-state-incomplete; the GCGR component contribution to appetite biology is sparser than the GLP-1R-mediated central appetite-suppression mechanism, with hepatic and energy-expenditure axes carrying more of the mechanism-class-distinct effect.
Energy-expenditure phenotype. Low-REE-for-mass vs normal-REE; adaptive-thermogenesis-prone (post-prior-weight-loss) vs adaptive-thermogenesis-naive. Survodutide-specific consideration: GCGR-mediated thermogenesis in brown adipose tissue (canonical §2.3) and the parallel hepatic-fat-mobilization pathway may have differential effect-magnitude in the low-REE phenotype and in the adaptive-thermogenesis-prone phenotype. Research-state-incomplete; mechanism-research-active direction (NCT06745284 Phase 1 ACTIVE_NOT_RECRUITING; primary completion 2027-01-08; will quantify energy expenditure and fatty acid oxidation against an active comparator).
Comorbidity load. Monocondition (CWM alone) vs polycondition (CWM + T2D + MASH + CKD + ASCVD). The SYNCHRONIZE program covers monocondition (SYNCHRONIZE-1) and polycondition (SYNCHRONIZE-2 obesity + T2D; SYNCHRONIZE-CVOT obesity + CVD/CKD/≥2 weight-related complications; SYNCHRONIZE-MASLD obesity + NASH) phenotype contexts. Survodutide-specific consideration: the polycondition phenotype with MASH or MASH-suspected-fibrosis component is the phenotype where the dual-receptor mechanism class may provide differential benefit; the LIVERAGE F2/F3 and F4 trials specifically address the fibrosis-stratified MASH phenotype.
Pharmacologic history. Prior GLP-1 RA exposure (response / non-response / intolerance to semaglutide, liraglutide, dulaglutide, exenatide, tirzepatide, or oral non-peptide GLP-1R agonists), prior bariatric surgery with weight regain, prior weight-loss-pharm exposure (phentermine / topiramate / naltrexone-bupropion / orlistat). Survodutide-specific consideration: prior-GLP-1-RA-non-response phenotype and prior-tirzepatide-intolerance phenotype are candidate phenotypes for survodutide trial enrollment and (post-approval) for survodutide consideration in non-response algorithms (§7) — the dual-receptor profile is mechanistically distinct from prior agents.
Life-stage modifier. Reproductive-age female (pregnancy planning is a discontinuation trigger per §8 with the survodutide ~6-day half-life arithmetic and the 2-month pre-conception window); perimenopausal / menopausal; older adult (≥65, lean-mass concern — canonical §6.13.3 catabolic / cortisol axis considerations are research-state for chronic GCGR activation); adolescent (no survodutide pediatric trial as of 2026-05-13; research-direction-future).

Phenotype-targeting framing for the pre-approval state (Pattern AA). Because survodutide is pre-FDA-approval as of 2026-05-13, phenotype-targeting at the clinical-practice level operates through (a) trial enrollment matching for active SYNCHRONIZE-CVOT, LIVERAGE, LIVERAGE-Cirrhosis, ARROW Phase 2 CKD, and survodutide Phase 1 trials — patients whose phenotype matches an active trial’s enrollment criteria are candidates for trial participation; (b) anticipated post-approval phenotype-targeting that this protocol prepares clinicians to apply once survodutide gains FDA approval and a specific indication-scope label is established. Pattern R.1 enforcement: phenotype-targeting framing leads with what the phenotype-targeted use case IS, not with the regulatory-deficit framing.

1.4 Cross-reference to case construction

Worked clinical cases for survodutide in pre-approval state are constructed against (a) the active SYNCHRONIZE + LIVERAGE + ARROW Phase 2 program enrollment criteria for patients considered for trial participation; (b) the anticipated post-approval phenotype-targeting framework for clinical-education preparation. Cases are not constructed against current-prescribing scenarios in the general patient population because survodutide is not in current FDA-approved prescribing as of 2026-05-13. Pre-approval-state cases involving compounded survodutide where it appears in clinical practice are constructed against the Pattern Z calibration anchor 2 framing with pre-approval-compound adaptation per §10.3.

1.5 Worked example — the polycondition phenotype with MASH F2/F3 facing the pre-approval survodutide question

A representative clinical-education case for the pre-approval state: a 56-year-old male presents with BMI 33, T2D (HbA1c 7.9 on metformin + semaglutide 1.0 mg ongoing for 14 months with on-trajectory weight loss of approximately 9% but persistent hepatic transaminase elevation), biopsy-confirmed MASH with F2 fibrosis (NAS 5; biopsy 2024), FibroScan 11 kPa (indeterminate-to-high fibrosis range), eGFR 71, UACR 28 mg/g, no MTC / MEN-2 family history, no pancreatitis history, no gastroparesis, no prior NAION, no active retinopathy, no active eating disorder.

This patient’s phenotype matches the anticipated survodutide LIVERAGE (F2/F3 MASH) enrollment scope and the anticipated SYNCHRONIZE-MASLD enrollment scope. His hepatic-IR-dominant ectopic-fat-positive phenotype with confirmed F2 fibrosis is the phenotype where the survodutide GLP-1R + GCGR dual-receptor mechanism class — particularly the hepatic GCGR activation component — is anticipated to provide differential benefit beyond his current GLP-1R monotherapy. Pre-approval-state options:

(a) Active trial enrollment in LIVERAGE F2/F3. LIVERAGE (NCT06632444) is RECRUITING as of 2026-05-13 per ClinicalTrials.gov v2 API verification (canonical §3.3). For this patient with biopsy-confirmed MASH F2 fibrosis, the LIVERAGE enrollment criteria are anticipated to align (specific enrollment criteria per the ClinicalTrials.gov registration). Trial-enrollment option requires the patient to discontinue his current semaglutide regimen per the trial protocol’s washout requirements (typical Phase 3 washout for prior GLP-1 RA exposure ~5 half-lives ≈ 35 days for semaglutide); this washout decision is a clinically meaningful trade-off that the patient and clinician evaluate jointly.
(b) Continue current regimen. Semaglutide 1.0 mg for T2D + CV-risk benefit (per SUSTAIN-6 PMID 27633186 and SELECT PMID 37952131 indications, with FLOW PMID 38785209 for the CKD-risk component) is FDA-approved for marketing claims and his current regimen. Semaglutide is also FDA-approved for marketing claims for MASH F2/F3 (per the ESSENCE Phase 3 readout, Sanyal AJ et al. NEJM 2025 Jun 05, PMID 40305708) — this is the same first-author Sanyal AJ as the survodutide Phase 2 MASH publication PMID 38847460, but the two trials are distinct (ESSENCE is semaglutide Phase 3; survodutide trial is Phase 2). The patient’s current regimen at semaglutide 1.0 mg is below the FDA-approved MASH dose (semaglutide 2.4 mg for MASH per ESSENCE); a dose escalation to 2.4 mg semaglutide for the MASH indication is one option within his current FDA-approved-for-marketing-claims regimen.
(c) Continue current regimen plus prepare for anticipated survodutide availability post-approval. This is the clinical-education framing this protocol supports: the clinician understands the anticipated survodutide profile, anticipates the patient’s phenotype match to the post-approval MASH indication scope, and prepares to revisit the regimen decision once survodutide is FDA-approved.
(d) Compounded survodutide acquisition (with the pre-approval-compound regulatory considerations developed in §10.3). Compounded survodutide is a clinical-practice reality that some patients and clinicians ask about; the pre-approval-compound regulatory landscape operates under different dynamics than the post-FDA-approval shortage-driven 503A/503B framework that applied to compounded semaglutide and tirzepatide during 2022-2024 shortage periods. The §10.3 framing applies — Pattern Z calibration anchor 2 with pre-approval-compound adaptation.

Pattern Z calibration applied to §1.5. The pre-approval-state options are presented factually; no option is steered. Trial enrollment is presented as a real option for this patient. Continuation of current FDA-approved-for-marketing-claims regimen is presented as a real option, including the dose-escalation-to-2.4 mg-semaglutide-for-MASH option which is a current FDA-approved-for-marketing-claims option. The prepare-for-anticipated-survodutide option is presented as a real option. Compounded survodutide acquisition is presented as a real option with the §10.3 regulatory-context framing. The patient and clinician decide.

Pattern AA precision applied to §1.5. Every regulatory claim in the case carries its qualification: semaglutide is FDA-approved-for-marketing-claims for T2D (Ozempic), chronic weight management (Wegovy), cardiovascular risk reduction in adults with obesity + established CVD without diabetes (per SELECT 2024 label expansion), CKD risk reduction in T2D (per FLOW 2025 label expansion), and MASH F2/F3 (per ESSENCE 2025 label expansion). Survodutide is pre-FDA-approval-for-marketing-claims as of 2026-05-13; FDA Breakthrough Therapy designation for MASH has been granted (regulatory-procedural status, not approval); SYNCHRONIZE Phase 3 obesity portfolio readouts are pending peer-reviewed publication; LIVERAGE Phase 3 readouts are pending in 2029-2031.

Pattern AB.1 disambiguation discipline applied to §1.5. The PMIDs cited above are disambiguated against the canonical’s Phase 4 AB-hygiene companion document. PMID 38847460 is survodutide Phase 2 MASH (Sanyal AJ et al.). PMID 38856224 is tirzepatide SYNERGY-NASH Phase 2 MASH (Loomba R et al.) — same NEJM publication date (2024-07-25), distinct compounds and trials. PMID 40305708 is semaglutide ESSENCE Phase 3 MASH F2/F3 (Sanyal AJ et al., 2025 Jun 05) — same first-author Sanyal AJ as PMID 38847460 but different compound, different trial, different journal date, different phase. PMID 36934740 is semaglutide Loomba 2023 Phase 2 in NASH-related cirrhosis F4 — primary fibrosis-improvement endpoint not statistically significant. The §11 Bibliography enforces the disambiguation at every citation occurrence.

2. Selection criteria (inclusion / exclusion / contraindications)

2.1 Purpose

Define who survodutide is anticipated to be for, who is anticipated to require clinician-judgment posture, and who is anticipated to be a hard-contraindication exclusion — under the pre-FDA-approval-state framing. Section 2 operationalizes the anticipated indication scope from Section 1 into actionable clinical screening criteria that prepare clinicians for the post-approval state and that inform clinical-judgment for current trial enrollment, investigational-supply use, or compounded-survodutide-where-it-appears-in-clinical-practice considerations.

The section is structured into three sub-blocks: anticipated inclusion criteria (positive criteria — the patient phenotype that the SYNCHRONIZE + LIVERAGE Phase 3 program enrolled and that the anticipated FDA label will permit; subject to peer-reviewed primary publication of the Phase 3 readouts), anticipated relative exclusion criteria (phenotypes where benefit is uncertain or risk is elevated, requiring case-by-case clinical judgment), and anticipated contraindications (hard stops, anchored to FDA boxed warning and labeled contraindication class precedents from the GLP-1 RA class plus survodutide-specific glucagon-receptor-component considerations).

Pattern R.1 enforcement at this section: the section opens with anticipated inclusion criteria — who the molecule is anticipated to be for — before exclusions and contraindications. Pattern R.1 design-time ordering: 2.2 anticipated inclusion → 2.3 anticipated relative exclusion → 2.4 anticipated contraindication. Reversing the order is a Pattern R.1 violation regardless of paragraph-level Pattern R compliance.

Pattern AA enforcement at this section: anticipated contraindications are sourced from the GLP-1 RA class precedent (FDA boxed warning for MTC and MEN-2; pancreatitis precaution / labeled cautionary use; hypersensitivity contraindication; pregnancy labeled contraindication for CWM indications) and from survodutide-specific glucagon-receptor-component clinical-judgment considerations. The phrasing throughout this section reflects the anticipated-pending-Phase-3-readouts framing — every regulatory claim is stated as anticipated, with the explicit qualification that the survodutide-specific FDA label is not yet published and that label-language confirmation awaits FDA submission and review.

2.2 Anticipated inclusion criteria — the trial-enrolled and label-permitted phenotype

Anticipated inclusion criteria are stated as the populations the Phase 2 and Phase 3 programs have enrolled and that the anticipated FDA label is expected to permit per the SYNCHRONIZE + LIVERAGE trial design. The protocol specifies, for each anticipated indication category from §1.2, the inclusion criteria with primary-source anchoring to the relevant trial enrollment.

Chronic weight management — obesity / overweight without T2D (anticipated, per SYNCHRONIZE-1 enrollment). Adults age ≥18 with overweight or obesity per the SYNCHRONIZE-1 enrollment criteria (specific BMI threshold per the ClinicalTrials.gov registration; anticipated BMI ≥30 or BMI ≥27 with weight-related comorbidity per the Module 5 CWM-indication class precedent). Trial-program effect-size anchor for the inclusion sub-population: SYNCHRONIZE-1 sponsor topline approximately 16.6% body-weight reduction at 6.0 mg vs placebo at 76 weeks (peer-reviewed primary publication pending) and Phase 2 dose-finding (le Roux 2024 PMID 38330987) approximately −14.9% at 4.8 mg at 46 weeks.

Chronic weight management with T2D — obesity + T2D (anticipated, per SYNCHRONIZE-2 enrollment). Adults age ≥18 with overweight or obesity plus T2D per the SYNCHRONIZE-2 enrollment criteria (76 weeks; n≈870; COMPLETED 2025-12-12; peer-reviewed primary publication pending). The T2D inclusion criterion is anticipated to include HbA1c range and antidiabetic-therapy-baseline conditions consistent with the Module 5 T2D-indication class precedent.

Cardiovascular outcomes — obesity + established CVD or CKD or ≥2 weight-related complications (anticipated, per SYNCHRONIZE-CVOT enrollment). Adults age ≥18 with overweight or obesity plus established cardiovascular disease, or chronic kidney disease, or at least two weight-related complications or risk factors for CVD per the SYNCHRONIZE-CVOT enrollment criteria (event-driven design; ACTIVE_NOT_RECRUITING; primary completion 2026-05-01). The cardiovascular-outcomes inclusion phenotype is class-comparator-relevant to SELECT semaglutide (Lincoff 2023 PMID 37952131; n=17,604 adults with BMI ≥27 + established CVD without diabetes; MACE HR 0.80) — but the SYNCHRONIZE-CVOT enrollment broadens beyond established-CVD-only to include CKD and weight-related-complications-positive phenotypes.

MASH F2/F3 — non-cirrhotic MASH with F2-F3 fibrosis (anticipated, per LIVERAGE enrollment). Adults with biopsy-confirmed or imaging-confirmed MASH with F2-F3 fibrosis per the LIVERAGE enrollment criteria (RECRUITING; primary completion 2031-12-27). Trial-program effect-size anchor: Phase 2 MASH Sanyal 2024 PMID 38847460 — 62% MASH resolution at 6.0 mg vs 14% placebo at 48 weeks; dose-responsive fibrosis improvement of at least one stage without worsening MASH 64% at 6.0 mg vs 26% placebo.

MASH F4 compensated cirrhosis (anticipated, per LIVERAGE-Cirrhosis enrollment). Adults with biopsy-confirmed compensated NASH/MASH cirrhosis (F4) per the LIVERAGE-Cirrhosis enrollment criteria (RECRUITING; primary completion 2029-06-05). The F4-cirrhosis-population inclusion is the first Phase 3 enrollment for a GLP-1 / glucagon dual agonist in compensated cirrhosis. The cirrhosis-population dosing is anticipated to be informed by the Phase 1 cirrhosis-population PK characterization (Lawitz 2024 PMID 38857788; NCT05296733).

Obesity + NASH overlap (anticipated, per SYNCHRONIZE-MASLD enrollment). Adults with obesity plus presumed or confirmed NASH per the SYNCHRONIZE-MASLD enrollment criteria (48 weeks; COMPLETED 2025-10-09; peer-reviewed primary publication pending). This indication captures the clinically common overlap population distinct from the histology-confirmed-fibrosis LIVERAGE design.

Regional CWM (Japan, China — SYNCHRONIZE-JP, SYNCHRONIZE-CN). Regional Phase 3 inclusion criteria per the registry; FDA submission scope likely does not directly include the regional trials but the regional data inform pooled efficacy/safety characterization.

Anticipated chronic kidney disease (ARROW Phase 2; very early). Adults with chronic kidney disease per the ARROW Phase 2 enrollment criteria (NCT07206290; investigator-initiated; NOT_YET_RECRUITING; primary completion 2027-11-30). Albuminuria reduction primary endpoint.

2.3 Anticipated relative exclusion criteria — clinician-judgment phenotype

Anticipated relative exclusion criteria identify phenotypes where the molecule is anticipated to require clinician-judgment posture but is not anticipated to be a hard contraindication. The protocol’s structure for each relative exclusion is: state the criterion; state the underlying concern; state the magnitude of available evidence; state the recommended clinician-judgment posture; flag the survodutide-specific glucagon-receptor-component considerations where applicable.

Severe gastroparesis or gastroparesis-predisposing comorbidity. GLP-1R-mediated delayed gastric emptying is anticipated to be a survodutide AE-class component (canonical §6.3). In established severe gastroparesis, anatomical and symptomatic worsening risk is elevated; SYNCHRONIZE and LIVERAGE trial programs are anticipated to have excluded severe gastroparesis per the Module 5 GLP-1 RA class precedent. Clinician-judgment posture for clinical use once approved.
Active or recent (within 12 months) acute pancreatitis. Distinct from prior severe-pancreatitis-history (a §2.4 anticipated contraindication for severe history). Recent acute pancreatitis is anticipated to be a relative exclusion with clinician-judgment posture per the Module 5 GLP-1 RA class precedent.
Severe gastrointestinal disease (active IBD flare; severe GERD with esophagitis). Relative — GLP-1R-mediated GI AE profile may exacerbate.
Diabetic retinopathy with rapid HbA1c improvement risk (T2D indication context). Class-level signal for the GLP-1 RA class per the SUSTAIN-6 retinopathy-complication finding. In T2D patients with proliferative retinopathy or advanced background DR, ophthalmology pre-treatment evaluation is the recommended posture. Survodutide-specific retinopathy event reporting per the SYNCHRONIZE-2 obesity + T2D readout will inform once published.
Severe renal impairment (eGFR <15) outside Phase 1 renal-impairment PK characterization (NCT06352411; COMPLETED 2025-09-16; primary publication may follow). For anticipated CKD-indication use (ARROW Phase 2; future), the trial population is anticipated to address CKD across renal-function strata; specific dose-adjustment considerations are anticipated to follow the Phase 1 renal-impairment PK characterization.
Severe hepatic impairment (Child-Pugh C) outside LIVERAGE-Cirrhosis enrollment. The LIVERAGE-Cirrhosis trial enrolls compensated cirrhosis (F4); decompensated cirrhosis (Child-Pugh C) is anticipated to be outside the trial enrollment scope and therefore outside the anticipated label scope for MASH F4 indication. Clinician-judgment posture for decompensated-cirrhosis-population considerations.
Active eating disorder (anorexia nervosa, bulimia nervosa, BED with active purging). Class-precedent relative exclusion / contraindication for the appetite-suppression mechanism.
Active malignancy on therapy (other than MTC/MEN-2 contraindication — see §2.4). Trial programs typically exclude active cancer; clinician judgment with oncology co-management.
Glucagon-receptor-component clinical-judgment phenotypes (survodutide-specific). Three survodutide-class-specific relative-exclusion considerations from canonical §6.13:
- Baseline hyperglycemia surveillance. Survodutide is anticipated not to produce clinically significant hyperglycemia at therapeutic doses (the GLP-1R:GCGR activity ratio was engineered to avoid this; Thomas L et al. Diabetes Obes Metab 2024 PMID 38560764). Patients with poorly controlled hyperglycemia at baseline (e.g., HbA1c >9.0 with concurrent insulin or sulfonylurea on suboptimal regimen) are anticipated to require closer glycemic monitoring during survodutide titration; this is a mechanism-rationale-based clinician-judgment posture, not a contraindication.
- Baseline hepatic transaminase elevation interpretation. Survodutide’s GCGR-mediated fatty-acid mobilization mechanism is anticipated to produce transient transaminase elevation during titration (canonical §6.13.2). In MASH/MASLD populations, transaminase trajectory is anticipated to improve as MASH resolves; in patients with baseline elevation from non-MASH etiology (viral hepatitis, drug-induced liver injury, autoimmune hepatitis), the survodutide-mechanism-related transaminase pattern may complicate interpretation. Clinician-judgment posture for baseline-elevation-from-non-MASH-etiology phenotypes.
- Catabolic / cortisol axis considerations in lean-mass-vulnerable phenotypes (elderly, athletic, baseline sarcopenia). GCGR-mediated hepatic amino-acid catabolism (canonical §6.13.3) is anticipated to be a survodutide-class-specific consideration for lean-body-mass preservation; chronic-state implications beyond trial duration are research-state. Clinician-judgment posture for lean-mass-vulnerable phenotypes — protein intake recommendations (~1.2-1.6 g/kg/day under active weight loss), resistance training adjuncts.

2.4 Anticipated hard contraindications — boxed warnings and labeled contraindications (anticipated, per class precedent)

Anticipated hard contraindications are anchored to the GLP-1 RA class precedent and to survodutide-specific glucagon-receptor-component considerations. Each anticipated contraindication is documented with its source classification anticipation (FDA boxed warning vs labeled contraindication vs strong-evidence post-marketing signal). The phrasing throughout reflects the pre-approval-state framing — the survodutide-specific FDA label is not yet published as of 2026-05-13.

Personal or family history of medullary thyroid carcinoma (MTC). Anticipated FDA boxed warning per the GLP-1 RA class precedent based on rodent C-cell tumorigenicity signal (Bjerre Knudsen L et al. Endocrinology 2010 PMID 20203154). Human MTC signal in the GLP-1 RA class is debated per Silverii GA et al. Diabetes Obes Metab 2024 (PMID 38018310) and the Ko et al. Ann Intern Med 2026 SR + meta-analysis (PMID 41359966); the boxed-warning-mandated contraindication is class-wide and is anticipated to apply to survodutide. Anticipated absolute contraindication.
Multiple Endocrine Neoplasia syndrome type 2 (MEN-2). Same source — boxed-warning-mandated, anticipated class-wide absolute contraindication.
Severe prior pancreatitis history (severe acute or chronic). Anticipated labeled contraindication or strong-precaution depending on the FDA label language once published; class-precedent posture is precaution / labeled cautionary use, with severe history treated as contraindication for new initiation per clinician judgment.
Known serious hypersensitivity to survodutide or excipient. Anticipated labeled contraindication per standard pharmaceutical-product hypersensitivity-contraindication discipline.
Pregnancy (for anticipated CWM and MASH indications). Anticipated labeled contraindication for CWM-indication use per the GLP-1 RA class precedent. Pregnancy is a §8 discontinuation trigger, not a §2 inclusion-screen-only criterion — a patient on protocol who becomes pregnant transitions out of protocol immediately. The survodutide-specific pharmacokinetic context: approximately six-day elimination half-life supports ~30-35 day pharmacokinetic clearance (5 half-lives); 2-month pre-conception washout is anticipated to be the class-precedent recommendation pending the FDA label.

2.5 Worked example — survodutide anticipated selection criteria applied to the §1.5 polycondition MASH F2 case

The 56-year-old male in §1.5 with BMI 33, T2D HbA1c 7.9 on metformin + semaglutide 1.0 mg, biopsy-confirmed MASH F2 fibrosis, eGFR 71, UACR 28, no MTC / MEN-2, no pancreatitis history, no gastroparesis, no NAION, no active retinopathy.

Anticipated inclusion criteria. Patient meets anticipated SYNCHRONIZE-2 (obesity + T2D), SYNCHRONIZE-MASLD (obesity + presumed/confirmed NASH), and LIVERAGE (MASH F2/F3) anticipated inclusion criteria. His BMI 33 + T2D + biopsy-confirmed MASH F2 phenotype matches the load-bearing trial enrollment scopes. SYNCHRONIZE-CVOT enrollment criteria (established CVD, CKD, or ≥2 weight-related complications) — anticipated match depending on whether his T2D + MASH + obesity profile satisfies the ≥2 weight-related complications criterion per the trial registry definition.

Anticipated relative exclusion criteria. Patient does not have severe gastroparesis, recent acute pancreatitis, severe GI disease, severe renal or hepatic impairment, active eating disorder, or active malignancy. He is on prior GLP-1 RA (semaglutide 1.0 mg ongoing) — this is anticipated to require a washout period if entering a survodutide trial, with the specific washout per the trial protocol’s prior-GLP-1-RA-exposure handling. Pre-approval-state clinical-use consideration: the prior-GLP-1-RA pharmacologic history is anticipated to inform but not exclude survodutide consideration once approved. Survodutide-specific clinician-judgment phenotype: baseline transaminase elevation in the MASH F2 context — clinician anticipates transient transaminase elevation during survodutide titration with subsequent improvement as MASH resolves per the Sanyal 2024 Phase 2 MASH trial pattern (PMID 38847460).

Anticipated hard contraindications — none triggered. No MTC/MEN-2 family history; no severe prior pancreatitis; no hypersensitivity; not pregnant (male patient; not applicable). The patient does not trip any anticipated hard contraindication for survodutide.

Pre-approval-state decision. The patient is anticipated to be eligible for survodutide post-approval; he is also eligible for LIVERAGE F2/F3 trial enrollment per the anticipated trial-enrollment criteria. The clinical-education decision (per §1.5) is whether to (a) pursue trial enrollment in LIVERAGE F2/F3 (requires washout of current semaglutide), (b) continue current regimen with dose escalation of semaglutide to the FDA-approved-for-marketing-claims 2.4 mg MASH dose per ESSENCE, (c) continue current regimen and prepare for anticipated survodutide availability post-approval, or (d) consider compounded survodutide acquisition per the §10.3 pre-approval-compound framing. The patient and clinician decide.

Pattern AA precision in §2.5. “FDA boxed warning for MTC and MEN-2 (anticipated class-wide for GLP-1 RAs including survodutide)” is the precise anticipated regulatory framing — class-wide for GLP-1 RAs by the rodent C-cell mechanism precedent; not yet specific to survodutide because the survodutide-specific FDA label is not yet published. “Anticipated labeled contraindication for hypersensitivity and pregnancy” reflects the class-precedent expectation pending the survodutide-specific label. “Anticipated relative exclusion for severe gastroparesis” reflects clinician-judgment posture per class precedent.

Pattern V cross-check at §2.5. The retinopathy signal from SUSTAIN-6 (Marso 2016 PMID 27633186) is a direction-of-effect verification anchor for the GLP-1 RA class — trial documented complication signal in rapid-HbA1c-improvement sub-population, not in the overall trial population. Anticipated application to survodutide: in the SYNCHRONIZE-2 obesity + T2D trial readout, retinopathy event reporting per primary publication will inform the survodutide-specific retinopathy signal. Direction-of-effect for survodutide-specific retinopathy in the non-DR or mild-DR sub-population is research-state-pending. The NAION class-context (Lakhani I et al. Am J Ophthalmol 2025 PMID 40383360) documented an optic nerve and retinal adverse-event signal associated with semaglutide and absent for tirzepatide at the same analytic threshold — survodutide-specific NAION signal characterization will emerge from the SYNCHRONIZE + LIVERAGE program safety reporting; Phase 2 trial reporting may be too small for robust NAION signal detection. Pattern V framing: do not generalize the semaglutide NAION signal to survodutide, do not assume absence of signal in survodutide, and do not infer signal direction from absence of detection in Phase 2.

Pattern AB.1 disambiguation check at §2.5. PMID 38847460 (survodutide Sanyal 2024) ≠ PMID 38856224 (tirzepatide SYNERGY-NASH Loomba 2024) ≠ PMID 40305708 (semaglutide ESSENCE Sanyal 2025) ≠ PMID 36934740 (semaglutide cirrhosis Loomba 2023). Every citation in this section is content-verified to its intended compound and trial.

3. Pre-treatment workup

3.1 Purpose

Define the pre-treatment laboratory, imaging, and clinical-assessment workup that is anticipated to be completed and reviewed before survodutide initiation, whether under post-approval prescribing once survodutide gains FDA approval, under active trial enrollment in SYNCHRONIZE or LIVERAGE or ARROW Phase 2 (per the trial protocol’s specific workup requirements), under investigational-supply off-label use, or under compounded-survodutide-where-it-appears-in-clinical-practice considerations. Section 3 is the operational handoff between §2 (selection criteria) and §4 (initiation protocol): a patient who passes §2 anticipated screening enters §3 anticipated workup; only on workup completion does §4 anticipated dose initiation begin.

The survodutide-specific workup adds expanded hepatic transaminase baseline + monitoring posture to the standard Module 5 GLP-1 RA workup, reflecting the GCGR-mediated fatty-acid mobilization mechanism (canonical §6.13.2) and the survodutide-specific hepatic + glucagon-receptor-related safety considerations (canonical §6.13). The seven anticipated workup panels follow the Module 5 Protocol Template structure with survodutide-specific additions noted in §3.4 (MASH-specific panel — expanded) and §3.7.5 (survodutide-specific glucagon-receptor-component baseline).

This section cross-references the M5.9 Lab Panels — Patient Questions canonical, the canonical §8.5 laboratory framework, and the canonical §8.5.5 survodutide-specific monitoring question (“How do I monitor for hepatic + glucagon-receptor-related safety considerations identified in Section 6.13?”). Pattern W cross-section consistency: every lab listed in §3.2–§3.8 is reconciled with the §5 maintenance monitoring intervals (§5 cannot recommend a monitoring lab not established as a baseline lab in §3) and with the §6 AE management triggers (§6 cannot anchor an AE response to a lab not in the workup or monitoring panel).

3.2 Standard metabolic panel

Applies to every Module 5 protocol. Establishes baseline metabolic state, identifies undiagnosed comorbidity, and provides reference for monitoring.

Comprehensive metabolic panel (CMP). Sodium, potassium, chloride, CO₂, BUN, creatinine, glucose, calcium, total protein, albumin, ALT, AST, alkaline phosphatase, total bilirubin. Establishes hepatic and renal baseline for class-wide GLP-1 RA precautions and for any nephroprotective / hepatoprotective indication eligibility. Survodutide-specific note: ALT/AST baseline is load-bearing for the hepatic-transaminase-monitoring posture in §5.5 and §6.10 (survodutide-specific transaminase AE class).
Fasting lipid panel. Total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C, ApoB if available. Baseline for CV-risk indication eligibility (SYNCHRONIZE-CVOT anticipated indication context) and for monitoring metabolic improvement.
Fasting glucose and HbA1c. Establishes glycemic baseline regardless of indication. Survodutide-specific note: the GCGR-mediated counter-regulatory hyperglycemia mechanism (canonical §6.13.1) is mechanistically present but not clinically observed at therapeutic doses in the Phase 2 program; HbA1c + fasting glucose baseline supports the mechanism-rationale-based glycemic-monitoring posture in §5.5. For non-diabetic CWM indications, this also screens for undiagnosed prediabetes or T2D.
Body weight, height, BMI, waist circumference. Anthropometric baseline. Waist circumference is the visceral-adiposity-distribution anchor (§1.3 phenotype taxonomy).
Blood pressure (seated, two readings, standardized). Baseline for CV-risk indication eligibility and for monitoring (GLP-1 RA-mediated SBP reduction is a documented secondary effect; baseline BP context shapes hypertension co-medication adjustment).

3.3 Diabetes-specific panel (T2D indication or T2D comorbidity)

Applies when the protocol indication is T2D glycemic control (SYNCHRONIZE-2 anticipated indication context) or when the patient has T2D as a comorbidity within a CWM / CV / MASH / CKD indication.

HbA1c (above; standard panel). Confirms T2D diagnosis and severity.
Fasting C-peptide. Establishes endogenous insulin reserve — distinguishes T2D from latent autoimmune diabetes of adults (LADA) and from advanced beta-cell-failure T2D where GLP-1 RA monotherapy response may be attenuated.
GAD-65 antibodies and IA-2 antibodies (if LADA suspected). GLP-1 RAs are not first-line in confirmed autoimmune diabetes; misclassification of LADA as T2D is a Pattern V direction-of-effect risk.
Diabetes complication screen (if not within the last 12 months): dilated retinal exam (also a class-wide pre-treatment requirement — §3.7), urine albumin-to-creatinine ratio (UACR), monofilament / vibratory testing for diabetic neuropathy.
CGM data review if available. Establishes time-in-range baseline and hypoglycemia frequency baseline. Relevant for §5 dose-adjustment triggers in patients on concurrent insulin or sulfonylurea.

3.4 MASH-specific panel (MASH indication or MASH risk profile) — survodutide-specific expanded posture

Applies when the protocol indication is MASH (anticipated per LIVERAGE F2/F3 or LIVERAGE-Cirrhosis F4 once approved), when the indication includes MASH overlap (anticipated per SYNCHRONIZE-MASLD), or when the patient’s baseline phenotype suggests MASH risk (T2D + obesity + elevated AST/ALT on standard panel + waist circumference ≥102 cm men / ≥88 cm women). The survodutide-specific expanded hepatic posture reflects the GCGR-mediated fatty-acid mobilization mechanism and the hepatic-transaminase-monitoring discipline established at canonical §6.13.2 + §8.5.5.

AST, ALT, GGT, alkaline phosphatase, total and direct bilirubin. Hepatic-function baseline; AST/ALT ratio interpretation context. Survodutide-specific load-bearing baseline for the §5.5 hepatic-transaminase-monitoring posture.
Albumin, INR/PT. Hepatic synthetic function baseline; load-bearing for the LIVERAGE-Cirrhosis F4 anticipated indication and for clinician-judgment in compensated-cirrhosis populations.
Platelet count. Component of FIB-4 calculation.
FIB-4 score. Calculated non-invasive fibrosis score (age × AST / [platelets × √ALT]). Stratifies fibrosis risk: low <1.3, indeterminate 1.3–2.67, high >2.67.
Vibration-controlled transient elastography (VCTE / FibroScan) if FIB-4 indeterminate or high. Liver stiffness measurement (kPa) plus controlled-attenuation parameter (CAP) for steatosis quantification. Stratification: low <8 kPa, indeterminate 8–12 kPa, high >12 kPa for advanced fibrosis. MRI-based imaging (MRI-PDFF for steatosis; MRE for fibrosis) is the higher-resolution alternative where available.
Liver biopsy with NASH-CRN scoring is the histological gold standard for MASH diagnosis and fibrosis staging; the LIVERAGE F2/F3 enrollment criteria are anticipated to require biopsy- or imaging-confirmed MASH with F2-F3 fibrosis; the LIVERAGE-Cirrhosis F4 enrollment criteria are anticipated to require biopsy-confirmed compensated cirrhosis.
Hepatitis B surface antigen and Hepatitis C antibody. Rule out viral hepatitis as alternative or co-existing liver disease.
Iron studies (ferritin, transferrin saturation). Rule out hereditary hemochromatosis.
Autoimmune liver-disease screen if clinically indicated (ANA, anti-smooth muscle, anti-mitochondrial antibodies).
Survodutide-specific transaminase-interpretation anticipation. Baseline ALT/AST elevation in the MASH F2/F3 context is anticipated to improve with survodutide treatment per the Phase 2 MASH trial pattern (Sanyal 2024 PMID 38847460 reported transaminase normalization or improvement at the dose-responsive efficacy doses). Baseline ALT/AST elevation from non-MASH etiology (viral hepatitis, drug-induced, autoimmune) complicates the survodutide-mechanism-related transaminase pattern interpretation; clinician-judgment for baseline-elevation-from-non-MASH-etiology phenotypes (§2.3 anticipated relative exclusion consideration).

3.5 Kidney-specific panel (CKD indication or borderline baseline kidney function)

Applies when the protocol indication is anticipated to be CKD (per ARROW Phase 2 once available) or when baseline eGFR is 30–60 regardless of indication, or when the patient meets the SYNCHRONIZE-CVOT enrollment criterion for CKD as part of the cardiovascular outcomes indication.

Serum creatinine, eGFR. Standard renal-function baseline (also in §3.2 CMP).
Cystatin C-based eGFR if creatinine-eGFR is discordant with clinical picture (e.g., low muscle mass elderly patient with apparently normal creatinine but real GFR reduction).
Urine albumin-to-creatinine ratio (UACR). Quantifies albuminuria — the ARROW Phase 2 primary endpoint anchor and the class-comparator FLOW semaglutide enrollment criterion (UACR 100-5000).
Urinalysis with microscopy. Rules out alternative kidney disease (active sediment, hematuria, proteinuria pattern).
Serum bicarbonate, phosphorus, calcium, PTH if eGFR <60. Chronic-kidney-disease-mineral-and-bone-disorder workup; relevant for advanced CKD co-management.
Survodutide Phase 1 renal-impairment PK characterization context. NCT06352411 (COMPLETED 2025-09-16; primary publication may follow) characterizes population PK in mild, moderate, and severe renal impairment vs normal renal function — load-bearing for clinical-use dosing considerations in renal-impairment populations once survodutide is approved.

3.6 CV-risk-specific panel (CVOT indication or ASCVD risk profile)

Applies when the protocol indication is anticipated to be cardiovascular risk reduction (SYNCHRONIZE-CVOT anticipated indication context) or when baseline ASCVD risk profile is high regardless of indication.

ECG (12-lead). Baseline rhythm and conduction status; relevant for QT considerations in concurrent medications. The survodutide Phase 1 cardiac safety / QT study (NCT06200467; COMPLETED 2025-10-22; primary publication may follow) characterizes survodutide-specific QT effect under multiple-dose titration with moxifloxacin positive control.
High-sensitivity troponin if symptomatic baseline. Rules out unstable ASCVD; ACS within 60 days is typically a relative exclusion for new initiation pending CV stabilization per class precedent.
NT-proBNP or BNP if HFpEF-suspect (obesity + dyspnea on exertion + age ≥60). HFpEF in survodutide is research-state-undeveloped as a dedicated indication; SYNCHRONIZE-CVOT readout may inform secondary HFpEF-population characterization.
Echocardiogram if HFpEF-suspect. LV ejection fraction, diastolic-function indices, LV-mass index.

3.7 Organ-baseline panels (thyroid, pancreas, ophthalmology — class-wide for GLP-1 RAs)

Class-wide pre-treatment workup for any GLP-1 RA protocol, regardless of indication. Anchors to the §2.4 anticipated contraindications and to the §6 AE-management algorithms.

Thyroid baseline. TSH at minimum; neck examination for thyroid nodules. If personal or family history of MTC or MEN-2 is identified at this step, this is the anticipated §2.4 hard contraindication for survodutide per the GLP-1 RA class precedent and the protocol does not initiate. Routine calcitonin screening is not generally recommended.
Pancreas baseline. Serum lipase, serum amylase (lipase is more pancreas-specific). Triglycerides (hypertriglyceridemic pancreatitis is a distinct etiology). Pancreatitis-history documentation per §2.4.
Ophthalmology — dilated retinal examination. Particularly for T2D patients per the §3.3 diabetes-complication-screen overlap. Pre-treatment dilated exam for any T2D patient with HbA1c ≥9.0 or with known background DR is the recommended posture per the GLP-1 RA class precedent.
NAION pre-screen anticipation. The Lakhani 2025 (PMID 40383360) ophthalmologic class-context documented a signal associated with semaglutide and absent for tirzepatide at the same analytic threshold; survodutide-specific NAION signal characterization will emerge from the SYNCHRONIZE + LIVERAGE Phase 3 safety reporting. Pattern AA precision: NAION signal status for survodutide is research-state-pending as of 2026-05-13; clinician-judgment pre-screening for known optic-disc cupping, prior NAION, or unexplained visual symptoms reflects the class-context awareness without prejudging the survodutide-specific signal direction.

3.7.5 Survodutide-specific glucagon-receptor-component baseline (NEW for survodutide protocol)

This is the survodutide-specific addition distinct from the standard Module 5 GLP-1 RA workup. The framework reflects canonical §6.13 (glucagon-receptor-related safety considerations) and supports the §5.5 monitoring posture.

Baseline hepatic transaminases (already in §3.2/§3.4). Load-bearing for the survodutide-specific transaminase-interpretation discipline.
Baseline body-composition assessment (DXA or bioimpedance where available). Load-bearing for the lean-body-mass-preservation posture (canonical §6.13.3 catabolic / cortisol axis considerations).
Hand-grip strength or sit-to-stand timed test (functional strength baseline). Relevant for ≥65 age phenotype and athletic / lean-mass-vulnerable phenotypes.
Baseline fasting glucose / HbA1c (already in §3.2/§3.3). Load-bearing for the mechanism-rationale-based glycemic-monitoring posture per canonical §6.13.1.
Anticipated baseline review of MASH-suspected / MASH-confirmed status. Even for non-MASH-indication patients, the survodutide GCGR-mediated hepatic mechanism may produce transaminase patterns that clinician-judgment interprets against baseline MASH status; the §3.4 MASH-specific panel applies anticipatorily to MASH-risk-positive phenotypes.

3.8 Body-composition baseline

Applies to every Module 5 CWM protocol and to lean-mass-stack protocols. Establishes a baseline against which §5 monitoring tracks lean-mass preservation vs total-weight change.

Bioelectrical impedance analysis (BIA) or dual-energy X-ray absorptiometry (DEXA). Lean mass, fat mass, visceral adipose tissue if DEXA. DEXA is more accurate; BIA is more accessible.
Resting energy expenditure (REE) if indirect-calorimetry-equipped. Establishes energy-expenditure phenotype baseline (§1.3 phenotype taxonomy). Survodutide-specific research-direction: the NCT06745284 Phase 1 trial of energy expenditure and fatty acid oxidation will inform the survodutide-mechanism-specific energy-expenditure characterization (ACTIVE_NOT_RECRUITING; primary completion 2027-01-08).

3.9 Worked example — survodutide anticipated pre-treatment panel for the §1.5 polycondition MASH F2 case

The 56-year-old male in §1.5 (BMI 33, T2D HbA1c 7.9 on metformin + semaglutide 1.0 mg, biopsy-confirmed MASH F2, FibroScan 11 kPa, eGFR 71, UACR 28). Anticipated workup for a survodutide post-approval initiation or for LIVERAGE F2/F3 trial enrollment:

Standard metabolic panel (§3.2) including ALT/AST as the survodutide-specific load-bearing transaminase baseline (his baseline ALT/AST per his MASH F2 context is anticipated to be modestly elevated — baseline pattern documented).
Diabetes-specific panel (§3.3) including HbA1c (already 7.9), fasting C-peptide, dilated retinal exam given HbA1c >7.5 and prior 14-month semaglutide treatment (rapid HbA1c improvement during prior semaglutide titration; check for retinopathy stability), UACR (already 28; below FLOW enrollment range but within standard T2D monitoring).
MASH-specific panel (§3.4) — expanded for survodutide. Liver biopsy already performed; pattern is biopsy-confirmed MASH F2 with NAS 5. FibroScan 11 kPa (indeterminate-to-high range). FIB-4 calculated from his standard-panel values. Viral hepatitis screen and iron studies if not previously documented. Albumin and INR/PT for hepatic synthetic function baseline. Survodutide-specific transaminase baseline documentation: baseline ALT/AST pattern documented; anticipated improvement during survodutide titration per the Sanyal 2024 Phase 2 MASH pattern; clinician-judgment for the GCGR-mechanism-related transient transaminase pattern interpretation.
Kidney-specific panel (§3.5): UACR (already 28), urinalysis with microscopy, cystatin-C-eGFR if discordant; eGFR 71 is within standard T2D monitoring range.
CV-risk-specific panel (§3.6): ECG baseline; troponin not indicated (no symptomatic baseline); NT-proBNP if clinical features suggest HFpEF.
Organ-baseline panels (§3.7): TSH; neck exam (no MTC/MEN-2 family history per §1.5); lipase + amylase + triglycerides; ophthalmology dilated exam (already noted under diabetes-specific); NAION pre-screen — given prior 14-month semaglutide treatment without NAION event, the survodutide-anticipated-signal status is research-state-pending and the clinician’s posture is awareness without prejudgment.
§3.7.5 survodutide-specific glucagon-receptor-component baseline: baseline ALT/AST (above); body-composition DXA or BIA (his BMI 33 and prior 9% weight loss on semaglutide make body-composition tracking informative for the survodutide GCGR-mechanism-related lean-mass-preservation posture); hand-grip strength or functional strength test; mechanism-rationale-based glycemic-monitoring posture documented (his HbA1c 7.9 baseline supports the post-survodutide-initiation glycemic-tracking discipline).
Body-composition baseline (§3.8): DXA or BIA; REE if indirect-calorimetry-equipped.

Pattern W cross-check applied to §3.9. Every lab in the anticipated panel above is reconciled with §5 monitoring intervals (every monitoring lab is established as a baseline lab) and with §6 AE-management algorithms (every AE-trigger lab is in the workup). The protocol’s §11 Bibliography anchors each pivotal-trial enrollment lab convention to its NCT and PMID with Pattern AB.4 standing-scan verification.

Pattern AA precision in §3.9. Anticipated workup elements are stated as anticipated; pre-approval-state framing applies throughout. The specific workup for LIVERAGE F2/F3 trial enrollment per the trial protocol may differ from the anticipated post-approval workup and from this clinical-education anticipated panel; the trial protocol takes precedence for trial-enrolled patients.

4. Initiation protocol

4.1 Purpose

Define the anticipated starting dose, titration schedule, and tolerability-management cadence for survodutide initiation, anchored to the Phase 2 and Phase 3 program titration conventions and the survodutide-specific mechanism considerations. Section 4 is the time-sequenced action plan from Day 0 (first dose) through approximately Week 16-20 (target-dose attainment per the SYNCHRONIZE + LIVERAGE program titration schedule) — the period during which the patient transitions from naive to maintenance-stable.

§4 is the section where Pattern Z calibration is most operationally relevant to the survodutide pre-approval state. The initiation period is when patient adherence is most fragile, GI tolerability is most challenging, and clinician counseling has the greatest influence on continuation vs discontinuation. Pattern Z.injection-framing applies (Dr. Gross 2026-05-13 directive): the self-injection mechanics are framed as a routine subcutaneous injection technique the patient will learn through reconstitution training (where applicable for compounded preparations) and standard injection training; the protocol does NOT use “daunting,” “scary,” or “intimidating” framing for the self-injection mechanics. Pattern Z calibration anchor 4 (comparator framing) and anchor 5 (off-label / extrapolation transparency) appear in §10 counseling beats with the pre-approval-state framing.

4.2 Anticipated starting dose

The anticipated starting dose follows the Phase 2 and Phase 3 program convention: approximately 0.6 mg weekly as the tolerability-priming starting dose. This is sub-therapeutic for the target effect at maintenance dose; the purpose is GI-AE attenuation prior to escalation. The starting dose convention is anchored to the Phase 2 obesity dose-finding trial (le Roux 2024 PMID 38330987; starting dose 0.6 mg with stepwise escalation across 16-20 weeks to maintenance doses), the Phase 2 MASH trial (Sanyal 2024 PMID 38847460; 0.6 mg starting with 24-week titration to maintenance doses 2.4/4.8/6.0 mg), and the SYNCHRONIZE-1 Phase 3 trial dose escalation per the trial registry. Pattern AA precision: the 0.6 mg starting dose is the trial-program convention, NOT yet a label-recommended starting dose because the survodutide-specific FDA label is not yet published as of 2026-05-13.

4.3 Anticipated titration schedule

The anticipated titration schedule follows the Phase 2/3 program 16-20 week titration convention. The protocol documents both the anticipated standard schedule (matching the trial-program convention) and the anticipated slow-titration option (each interval doubled) for patients with GI tolerability challenges at any step. A patient on slow titration is not on a different protocol; they are on the standard protocol with a stretched timeline.

Anticipated standard schedule (trial-program convention; specific weeks per the published Phase 2 and the SYNCHRONIZE-1 registry):

Week 1–4: 0.6 mg weekly subcutaneous
Week 5–8: 2.4 mg weekly subcutaneous (or graded intermediate dose per the trial-specific titration pattern; the Phase 2 program included intermediate steps per the dose-finding design)
Week 9–12: 3.6 mg weekly subcutaneous (or graded intermediate dose)
Week 13–16: 4.8 mg weekly subcutaneous
Week 17 onward: 6.0 mg weekly subcutaneous (maintenance dose for the obesity and MASH indications per the Phase 3 high-efficacy dose)

The intermediate-step granularity per the SYNCHRONIZE-1 Phase 3 titration pattern is anticipated to be specified in the peer-reviewed primary publication once published; the dose-escalation pattern in the Phase 2 MASH trial (Sanyal 2024) used 0.6 → 1.2 → 2.4 → 3.6 → 4.8 → 6.0 mg over 24 weeks for the 6.0 mg arm. Total titration period: approximately 16-24 weeks to target maintenance dose, with the specific schedule per the trial protocol or per the post-approval FDA label once published.

Anticipated slow-titration option. Each interval doubled. Used for patients with persistent moderate-severity GI AE at any standard-schedule step. Total: approximately 32-48 weeks to target maintenance dose under slow titration.

4.4 GI tolerability management at each titration step

GLP-1R-mediated delayed gastric emptying, central appetite-pathway modulation, and direct GI-motility effects are anticipated to produce a characteristic AE profile for survodutide consistent with the GLP-1 RA class: nausea, vomiting, diarrhea, constipation, eructation, abdominal pain. The Phase 2 program data across obesity (PMID 38330987), MASH (PMID 38847460), and T2D (PMID 38095657) characterize the AE profile at frequencies consistent with the broader GLP-1 RA class; specific Phase 3 program AE frequencies will publish with the SYNCHRONIZE and LIVERAGE primary publications.

Anticipated management:

Nausea — first-line non-pharmacologic. Reduce meal size, slow eating pace, avoid greasy / high-fat meals, hydrate consistently.
Nausea — first-line pharmacologic. Ondansetron 4 mg PRN; consider scheduled dosing for moderate-severity nausea. Cross-reference with QT considerations in concurrent medications (Phase 1 NCT06200467 cardiac safety / QT study; primary publication may follow).
Vomiting — assessment. Distinguish protocol-related vomiting (expected, attenuates) from acute-pancreatitis-suspect vomiting (severe abdominal pain, persistent, with lipase elevation) — §6.4 algorithm.
Diarrhea / constipation. Bowel-pattern-specific management.
Volumetric titration adjustment. Persistent moderate-to-severe GI AE at any step is the trigger for slow-titration (§4.3) — hold at current dose for an additional 2–4 weeks before next escalation, or step down to prior dose if tolerability does not stabilize.

4.5 Survodutide-specific titration-period considerations

Two survodutide-class-specific considerations apply during the titration period, distinct from the standard single-GLP-1R-agonist titration framework:

Anticipated transient hepatic-transaminase elevation during titration (canonical §6.13.2). Glucagon-receptor agonism is anticipated to produce transient transaminase elevation during titration through fatty-acid mobilization into hepatocyte β-oxidation; the mechanism is parallel to the transaminase patterns observed during accelerated weight loss. The Phase 2 MASH trial reported transaminase normalization or improvement at the dose-responsive efficacy doses, consistent with the MASH-resolution histopathology endpoint. Mechanism-rationale-based monitoring: baseline ALT/AST documented (per §3.4); periodic ALT/AST during titration (every 4-8 weeks during the 16-20 week titration); clinician-judgment for the transient-elevation-vs-progression interpretation in MASH-confirmed patients and for the mechanism-related-vs-non-MASH-etiology interpretation in MASH-suspected-but-not-confirmed patients.
Anticipated glycemic monitoring during titration in non-T2D populations (canonical §6.13.1). The GCGR-mediated counter-regulatory hyperglycemia mechanism is anticipated to be mechanistically present but not clinically observed at therapeutic doses based on the Phase 2 program data. Mechanism-rationale-based monitoring: baseline fasting glucose / HbA1c (per §3.2); periodic during titration, particularly in patients with pre-diabetes or insulin-resistance markers. In T2D populations, standard HbA1c monitoring per diabetes care guidelines applies.

4.6 Early monitoring cadence

The early-monitoring cadence is the contact frequency during the initiation period. Anticipated Module 5 protocol cadence with survodutide-specific additions: contact at Week 2 (post-first-dose tolerability check), Week 4–6 (after first titration step), Week 8–12 (mid-titration tolerability and adherence; survodutide-specific ALT/AST + glucose check per §4.5), Week 16–20 (target-dose attainment confirmation and §5 transition).

Contact modality (in-person vs telehealth vs message) is practice-specific. Escalation triggers (any contact identifying severe GI AE, suspected pancreatitis, suspected gallbladder event, suspected NAION, significant unintended weight loss, or survodutide-specific moderate-or-greater transaminase elevation without clinical correlation) → in-person evaluation within 48 hours.

4.7 Self-injection framing (Pattern Z.injection-framing applied)

Patient self-injection of subcutaneous survodutide is a routine technique that patients learn through standard subcutaneous-injection training. The injection-mechanics conversation: prefilled pen or syringe presentation (anticipated commercial presentation once approved; Phase 1 formulation crossover studies are characterizing pre-filled syringe vs pre-filled pen bioequivalence — NCT06772532, NCT07071974, NCT07221591, NCT07407348, NCT07413913); abdomen / thigh / upper arm rotation; standard subcutaneous-injection technique; site-rotation documentation. For compounded survodutide (where present in clinical practice, §10.3), reconstitution with bacteriostatic water and measured-dose drawing technique with insulin syringe is the operational technique — established protocols apply per the compounding pharmacy’s documentation and the clinician’s reconstitution-training discipline.

Pattern Z.injection-framing precision (Dr. Gross 2026-05-13 directive). The self-injection mechanics are framed as a learnable technique that patients routinely master with standard training. The protocol does NOT frame self-injection as “daunting,” “scary,” “intimidating,” or as a barrier. The framing leads with what the technique IS (subcutaneous injection routine; comparable to insulin self-injection that millions of patients perform routinely) and supports the patient’s learning of the technique through the clinician’s standard injection-training discipline.

4.8 Worked example — survodutide anticipated initiation for the §1.5 polycondition MASH F2 case

The 56-year-old male in §1.5, anticipated initiation under post-approval prescribing (anticipated FDA approval pending) or under LIVERAGE F2/F3 trial enrollment (current option). The clinical-education walk-through assumes anticipated post-approval initiation for the worked example; trial-enrollment-specific initiation follows the LIVERAGE trial protocol.

Anticipated starting dose. Survodutide 0.6 mg subcutaneous weekly. Tolerability-priming dose.

Anticipated standard titration schedule (per Phase 2/3 program convention; specific weeks per the post-approval label or the LIVERAGE trial protocol once published). Week 1–4: 0.6 mg weekly. Week 5–8: 2.4 mg weekly (or per intermediate-step pattern). Week 9–12: 3.6 mg weekly. Week 13–16: 4.8 mg weekly. Week 17 onward: 6.0 mg weekly (anticipated maintenance dose for MASH F2 indication per the LIVERAGE design and the Phase 2 MASH dose-finding). Total anticipated titration period: 16-24 weeks. Pattern AA precision: this schedule reflects the trial-program convention; the post-approval label-recommended schedule may differ.

Anticipated slow-titration option if GI AE persistent moderate-severity at any step. Each interval doubled.

Anticipated tolerability management at each step. First-dose (0.6 mg, Week 1) GI AE profile: nausea is anticipated as the most common early AE — anticipated typically mild and self-limited within 5-7 days for many patients per the Phase 2 program data pattern; moderate or persistent nausea triggers ondansetron 4 mg PRN and reinforcement of meal-size and meal-composition counseling. Escalation to 2.4 mg (Week 5; or per intermediate-step pattern) is anticipated as a challenge step — nausea recurrence on dose increase is anticipated and counseled-for; if moderate-severity persists beyond 2 weeks at the higher dose, hold for an additional 2-4 weeks before escalating to the next dose (slow-titration de facto applied at this specific step).

Subsequent escalations follow the same hold-if-needed logic.

Survodutide-specific titration-period monitoring (§4.5). Baseline ALT/AST per §3.4 expanded panel; periodic ALT/AST every 4-8 weeks during titration. Anticipated baseline-to-titration ALT/AST trajectory in this MASH F2 patient: transient titration-period elevation possible per mechanism rationale; trajectory anticipated to improve as MASH resolves consistent with the Phase 2 MASH trial pattern (Sanyal 2024 PMID 38847460); clinician-judgment for the transient-elevation-vs-progression interpretation. Glycemic monitoring: HbA1c at Week 12 and Week 16-20 — given his T2D baseline and the GCGR-mechanism counter-regulatory consideration, mechanism-rationale-based glycemic-monitoring discipline applies. His prior semaglutide-induced HbA1c improvement (from baseline unstated to 7.9 over 14 months) supports a baseline GLP-1-RA-class response pattern; survodutide-specific HbA1c trajectory may differ given the dual-receptor profile.

Anticipated early monitoring cadence — survodutide. Week 2 (post-first-dose telehealth tolerability check), Week 5-6 (post-first-titration in-person or telehealth, with weight + BP + GI tolerability assessment), Week 9-12 (mid-titration weight + BP + tolerability + ALT/AST + HbA1c), Week 16-20 (target-dose attainment — weight + BP + ALT/AST + HbA1c + transition to §5 maintenance cadence). For MASH F2-confirmed populations, FibroScan / VCTE follow-up at Week 24-26 may be informative for non-invasive fibrosis trajectory tracking.

Pattern V applied to §4.8. Effect-size anchors at survodutide target dose: Phase 2 MASH (Sanyal 2024 PMID 38847460) demonstrated 62% MASH resolution without worsening fibrosis at 6.0 mg vs 14% placebo at 48 weeks in n=295 MASH F1-F3 fibrosis patients; the direction-of-effect is established for the Phase 2 dose-responsive MASH-resolution endpoint and the Phase 2 dose-responsive fibrosis-improvement endpoint (64% at 6.0 mg vs 26% placebo). LIVERAGE F2/F3 Phase 3 readout will provide the load-bearing Phase 3 evidence base; readout pending 2031-12. Pattern AA framing: the Phase 2 effect-size is anchored to the Sanyal 2024 trial-enrollment population (biopsy-confirmed MASH F1-F3 with NAS ≥4); Phase 3 LIVERAGE enrollment is anticipated to be MASH F2-F3 specifically (the F1 stage and the F4 stage are out of LIVERAGE F2/F3 scope; F4 is covered by LIVERAGE-Cirrhosis). Generalizing the Phase 2 effect-size to outside-Phase-2-enrollment phenotypes without re-anchoring is a Pattern V violation.

Pattern AA applied to §4.8. The trial-program-convention titration is anticipated but is not yet a label-recommended titration because the survodutide-specific FDA label is not yet published. The starting dose, dose escalation, and maintenance dose are anticipated to align with the trial program once approved; post-approval label-language confirmation awaits FDA submission and review.

Pattern Z.injection-framing applied to §4.8. The self-injection mechanics are framed as a routine subcutaneous injection technique. Specific to this MASH F2 patient transitioning from prior semaglutide self-injection (14 months of weekly subcutaneous): the survodutide self-injection technique is operationally similar to his existing semaglutide injection routine; the technique transition is anticipated to be straightforward. For a patient new to subcutaneous self-injection, the standard injection-training discipline applies. No “daunting” or “scary” framing.

5. Maintenance protocol

5.1 Purpose

Define the anticipated post-titration, target-dose-attained operating state of the survodutide protocol: anticipated target dose by indication, monitoring intervals (with survodutide-specific hepatic + glucagon-receptor-related monitoring discipline per canonical §6.13 and §8.5.5), dose-adjustment triggers, and the transition between maintenance and discontinuation (§8) or non-response algorithm (§7). Section 5 is the longest operational phase anticipated for a survodutide protocol once approved — for a patient who tolerates target dose and continues therapy, maintenance is open-ended for the duration of clinical benefit.

5.2 Anticipated target dose by indication

The anticipated target dose is the dose at which survodutide’s primary effect is demonstrated in the Phase 2 / Phase 3 program. Anticipated target doses by indication category (per the Phase 2 and Phase 3 trial design conventions; specific label-recommended doses per the FDA label once published):

Chronic weight management (CWM) — obesity without T2D (anticipated). Target dose 6.0 mg weekly subcutaneous per the SYNCHRONIZE-1 Phase 3 design and the April 2026 sponsor topline (16.6% body-weight reduction vs placebo at 76 weeks).
CWM with T2D — obesity + T2D (anticipated). Anticipated target dose per the SYNCHRONIZE-2 Phase 3 design (peer-reviewed primary publication pending; dose per the Phase 3 trial registry).
Cardiovascular outcomes — obesity + CVD/CKD/≥2 weight-related complications (anticipated). Anticipated target dose per SYNCHRONIZE-CVOT Phase 3 design (event-driven; ACTIVE_NOT_RECRUITING; primary completion 2026-05-01).
MASH F2/F3 (anticipated). Anticipated target dose 6.0 mg weekly subcutaneous per the Phase 2 MASH trial (Sanyal 2024 PMID 38847460) high-efficacy dose and the LIVERAGE F2/F3 Phase 3 design (RECRUITING; primary completion 2031-12-27). The Phase 2 dose-response demonstrated graded MASH resolution and fibrosis improvement across 2.4 / 4.8 / 6.0 mg with 6.0 mg achieving the highest histopathology endpoint magnitudes.
MASH F4 compensated cirrhosis (anticipated). Anticipated target dose per the LIVERAGE-Cirrhosis Phase 3 design (RECRUITING; primary completion 2029-06-05). Cirrhosis-population dose selection per the survodutide cirrhosis-population PK characterization (Lawitz 2024 PMID 38857788; NCT05296733).
Obesity + NASH overlap (anticipated). Anticipated target dose per SYNCHRONIZE-MASLD Phase 3 design (48 weeks; COMPLETED 2025-10-09; peer-reviewed primary publication pending).

Pattern AA precision: target doses across indications are anticipated per the trial-program convention; the post-approval label-recommended target dose for each FDA-approved indication may differ from the trial-program convention. The specific dose-titration to target dose is per §4 anticipated standard schedule.

5.3 Monitoring intervals

Anticipated monitoring intervals follow the Module 5 maintenance-phase convention with survodutide-specific additions reflecting the GCGR-component monitoring discipline. Typical cadence: 3-month visits during the first year on target dose, 6-month visits thereafter for stable patients. The exact cadence depends on indication and on baseline comorbidity burden.

The anticipated monitoring panel at each interval includes the survodutide-specific four-question structure (per canonical §8.5 four-question framework with §8.5.5 survodutide-specific addition):

§5.5.1 Body weight, BMI, BP, indication-specific labs. Standard Module 5 maintenance monitoring.
§5.5.2 Glycemic monitoring (T2D + non-T2D mechanism-rationale-based glycemic discipline). HbA1c or fasting glucose during titration and at maintenance, particularly in T2D and pre-diabetic populations. In non-T2D populations, mechanism-rationale-based confirmation that individual patient response aligns with the trial-population data (Phase 2 program showed no clinically significant hyperglycemia signal at therapeutic doses).
§5.5.3 Survodutide-specific hepatic transaminase monitoring (NEW for survodutide protocol; canonical §8.5.5). Periodic ALT/AST every 12-24 weeks at maintenance depending on baseline status. Acute transaminase elevation interpretation: distinguish drug-related transient elevation from underlying MASH/MASLD progression; clinical correlation with patient symptom status and concurrent hepatic biomarkers. In MASH populations, transaminase trajectory may improve with survodutide treatment per the Phase 2 MASH trial pattern (Sanyal 2024 PMID 38847460) reflecting MASH resolution / hepatic-fat reduction.
§5.5.4 Body composition / lean body mass markers (survodutide-specific). Baseline DXA or bioimpedance per §3.7.5 + §3.8; serial assessment during weight loss to track lean-body-mass preservation. The canonical §6.13.3 catabolic / cortisol considerations imply that GCGR-mediated hepatic amino-acid catabolism may modify the lean-body-mass response to weight loss; clinical mitigation involves protein intake recommendations (~1.2-1.6 g/kg/day under active weight loss) plus resistance training adjuncts. Frequency: DXA or BIA quarterly during year 1 maintenance, biannually thereafter for stable patients.
Annual or biennial organ-baseline panel reassessment (§3.7). Thyroid; pancreas baseline if symptomatic; ophthalmology per indication and per NAION-class-context awareness.

5.4 Dose-adjustment triggers

Anticipated dose adjustment in the maintenance phase is driven by three trigger categories: target-not-met (effect is sub-threshold for clinical benefit at current dose), target-overshoot (effect exceeds clinical target), and AE-emergent (new or worsening AE that responds to dose reduction).

Anticipated dose-adjustment options: hold dose (maintain current), titrate up (move to next label-permitted higher dose if not already at maximum), titrate down (move to prior dose for tolerability), or transition to non-response algorithm (§7) if maximum dose with appropriate trial duration has not produced clinical benefit.

Survodutide-specific dose-adjustment consideration: transient hepatic transaminase elevation during titration or early maintenance is anticipated per the GCGR-mechanism context (canonical §6.13.2); the mechanism-rationale-based response is clinician-judgment on the transient-elevation-vs-progression interpretation, NOT automatic dose-down. Sustained or clinically significant transaminase elevation with clinical correlation triggers the §6.10 survodutide-specific transaminase AE class algorithm — which is mechanism-rationale-based monitoring discipline, NOT regulatory-deficit framing.

5.5 Worked example — survodutide anticipated maintenance for the §1.5 polycondition MASH F2 case

The 56-year-old male in §1.5, at anticipated Month 6 on target dose 6.0 mg weekly subcutaneous (anticipated post-approval initiation context; LIVERAGE F2/F3 trial-enrollment context follows the trial protocol for monitoring).

Anticipated target dose. 6.0 mg weekly subcutaneous per the Phase 2 MASH high-efficacy dose and the anticipated LIVERAGE design.

Anticipated monitoring intervals. Quarterly during year 1 maintenance (Months 4, 7, 10, 13 after target-dose attainment). Every 6 months thereafter for stable patients.

At each anticipated maintenance visit (per §5.3 four-question structure):

§5.5.1 Body weight, BMI, BP, T2D + MASH indication-specific labs. Weight trajectory tracked against Phase 2 / Phase 3 program effect-size anchors (anticipated body-weight reduction at 6.0 mg per the Phase 2 obesity dose-finding and the Phase 3 sponsor topline). HbA1c monitoring per T2D standard care.
§5.5.2 Glycemic monitoring. HbA1c at Month 4 (anticipated to track survodutide-mediated glycemic improvement; mechanism-rationale-based confirmation that the GCGR-mediated counter-regulatory hyperglycemia mechanism is not clinically manifesting). His T2D baseline HbA1c 7.9 — anticipated improvement during survodutide maintenance.
§5.5.3 Survodutide-specific hepatic transaminase monitoring. Periodic ALT/AST every 12 weeks during year 1 maintenance. Anticipated trajectory: transient titration-period elevation possible; sustained improvement as MASH F2 resolves consistent with the Phase 2 MASH trial pattern. Clinician-judgment on the transient-elevation-vs-progression interpretation. FibroScan / VCTE at Month 6 and Month 12 to track non-invasive fibrosis trajectory. Biopsy at planned interval per LIVERAGE F2/F3 trial protocol (if trial-enrolled) or per clinician-judgment if standard-of-care.
§5.5.4 Body composition. DXA at Month 6 and Month 12. Lean-body-mass preservation tracked given his BMI 33 baseline and the survodutide GCGR-component catabolic-axis consideration. Resistance training adjunct counseling reinforced.

Anticipated dose-adjustment triggers — survodutide CWM + MASH indication context.

Target-not-met: anticipated <5% weight loss at Month 6 on 6.0 mg target dose with documented adherence would trigger transition to §7 non-response algorithm. For MASH-specific target: <0.5-stage improvement in non-invasive fibrosis trajectory plus persistent histopathology features at biopsy follow-up may inform clinician-judgment on continuation vs alternative-therapy transition.
Target-overshoot: rare in CWM but unintended weight loss below patient’s pre-specified target floor (e.g., BMI dropping below 22) triggers dose-down to 4.8 mg with re-evaluation. In T2D context, hypoglycemia risk on concurrent insulin or sulfonylurea would primarily trigger reduction of the concurrent agent rather than down-titration of survodutide (per Module 5 GLP-1 RA class precedent).
AE-emergent — survodutide-specific transaminase pattern: sustained ALT/AST elevation (e.g., ≥3× upper limit normal sustained at 8-week reassessment) with clinical correlation suggesting progression beyond mechanism-related transient elevation triggers §6.10 survodutide-specific transaminase AE class algorithm. Pattern AA precision: the survodutide-specific transaminase pattern is mechanism-rationale-based monitoring per canonical §6.13.2, NOT regulatory-deficit framing. Clinician-judgment for the mechanism-related-vs-progression interpretation; hepatology co-management if interpretation is uncertain or if pattern is sustained.

Pattern W cross-check at §5.5. The monitoring intervals above are reconciled with the §3 pre-treatment panel (every monitoring lab is established as a baseline lab — ALT/AST in §3.2 + §3.4; HbA1c in §3.2 + §3.3; UACR in §3.5; DXA in §3.8; FibroScan in §3.4) and with the §6 AE-management algorithms (every AE-trigger lab is in the monitoring schedule). The protocol explicitly states: lipase is monitored on symptom-prompted basis (abdominal pain), not on scheduled-interval basis, per the Module 5 class precedent on not screening with low-specificity labs absent symptom. Body-composition tracking is in the §5.5.4 quarterly-then-biannual schedule, reconciled with the §3.8 baseline DXA / BIA.

Pattern AA precision in §5.5. Anticipated target dose, anticipated monitoring intervals, and anticipated dose-adjustment triggers all reflect the trial-program convention plus the Module 5 maintenance-phase convention with survodutide-specific additions; the post-approval FDA label may specify different intervals or different adjustment thresholds. The clinical-education framing supports clinician preparation for the anticipated post-approval state.

Pattern V applied to §5.5. Effect-size anchors at survodutide target dose 6.0 mg are Phase 2 anchored (Sanyal 2024 PMID 38847460 for MASH; le Roux 2024 PMID 38330987 for obesity; Blüher 2024 PMID 38095657 for T2D) and Phase 3 sponsor-topline-anchored (SYNCHRONIZE-1 April 2026 press release for obesity 76-week effect-size). Phase 3 peer-reviewed primary publications pending will refine the effect-size anchoring. Generalization of Phase 2 effect-sizes to Phase 3 enrollment populations without re-anchoring at Phase 3 readout publication is a Pattern V violation.

6. Side-effect management

6.1 Purpose

Define the anticipated anticipatory framing and clinician response algorithms for the adverse-event categories that apply to survodutide. Section 6 is the AE-by-AE-class operational reference for the practice — what to expect, when to escalate, when to discontinue — with the survodutide-specific GCGR-component AE class additions (canonical §6.13 hepatic transaminase + glycemic + catabolic / cortisol).

The section follows the Module 5 Protocol Template structure (GI, gallbladder, pancreatitis, NAION class-context, injection site, hypoglycemia in T2D with concurrent agent) with survodutide-specific additions: §6.10 transaminase AE class; §6.11 glycemic-monitoring AE-class-equivalent; §6.12 catabolic-axis lean-mass-preservation AE-class-equivalent. Each AE class addressed in a standard sub-structure: anticipatory framing, identification, severity grading, first-line management, escalation triggers, discontinuation triggers.

Pattern R applies at this section: each AE-class sub-block opens with anticipatory framing — what the AE is, why it occurs, how common it is anticipated to be per the trial program — before management. Pattern V applies: AE-class signals are characterized with primary-source effect-size and population qualification (e.g., NAION class-context anchored to Lakhani 2025 PMID 40383360 with the explicit class-differentiation finding for semaglutide-vs-tirzepatide and the survodutide-specific status as research-state-pending).

6.2 GI AE class — the dominant AE class anticipated for survodutide per Phase 2 program

Anticipated anticipatory framing. GLP-1R-mediated delayed gastric emptying, central appetite-pathway modulation, and direct GI-motility effects are anticipated to produce the characteristic GLP-1 RA AE profile: nausea, vomiting, diarrhea, constipation, eructation, abdominal pain. The AE profile is anticipated to peak at dose-escalation and to attenuate within 2-4 weeks at stable dose, consistent with the GLP-1 RA class precedent. Phase 2 program prevalence per primary publications (PMID 38330987 obesity; PMID 38847460 MASH; PMID 38095657 T2D); Phase 3 program AE frequencies will publish with the SYNCHRONIZE and LIVERAGE primary publications.

Identification. Patient-reported during early-monitoring contacts (§4) and maintenance visits (§5). Standardized severity grading via CTCAE: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe, hospitalization indicated), Grade 4 (life-threatening). Most protocol-relevant GI AEs are Grade 1-2.

First-line management. Non-pharmacologic: meal-size reduction, slow eating pace, low-fat / non-greasy meal composition, hydration emphasis. Pharmacologic: ondansetron 4 mg PRN for nausea; loperamide PRN for diarrhea per standard dosing; osmotic laxative (polyethylene glycol) for constipation; reassurance and meal-pairing adjustments for eructation.

Escalation triggers. Grade 3 severity at any step. Persistent Grade 2 severity beyond 4 weeks at stable dose. Vomiting with severe abdominal pain (assess for pancreatitis — see §6.4). Significant unintended weight loss exceeding the protocol’s target trajectory.

Discontinuation triggers. Grade 3 GI AE that does not resolve with dose-down. Patient preference (a tolerable but unpleasant Grade 2 profile is a Pattern Z calibration point — the protocol does not override patient preference for discontinuation by framing tolerability as obligation).

6.3 Gallbladder AE class

Anticipated anticipatory framing. GLP-1 RA association with cholelithiasis and cholecystitis has been demonstrated across the GLP-1 RA class trial programs; mechanism is attributed to weight-loss-rate-related bile-supersaturation and to direct effects on gallbladder motility. Survodutide-specific gallbladder event reporting per Phase 2/3 trial primary publications; Phase 3 program data will provide the load-bearing prevalence characterization.

Identification. Symptom-prompted — right upper quadrant pain, post-prandial colicky pain, fever-and-pain combination. Ultrasound first-line; HIDA scan if functional cholecystitis suspected without stones.

First-line management. Symptomatic gallstones with confirmed cholelithiasis: surgical consultation per standard practice. Temporary survodutide hold during peri-operative window; resume at maintenance dose post-cholecystectomy if no other contraindication has emerged.

Escalation triggers. Acute cholecystitis with systemic signs (fever, leukocytosis, sepsis). Choledocholithiasis suspected (LFT pattern + dilated CBD on imaging) requires urgent ERCP or surgical consultation.

Discontinuation triggers. Recurrent symptomatic gallstones post-cholecystectomy with bile-acid-related pattern: clinician judgment.

6.4 Pancreatitis AE class

Anticipated anticipatory framing. Acute pancreatitis is a class-level GLP-1 RA pharmacovigilance signal per Wen et al. Endocrinol Diabetes Metab 2025 (PMID 40988099 — pooled SR + meta-analysis of pancreatitis + pancreatic cancer rates in GLP-1 RA-treated populations). Phase 2 survodutide trial pancreatitis reporting per primary publications; Phase 3 program data will provide the load-bearing characterization. Pattern V direction-of-effect: class-level Phase 3 trial data have not demonstrated a statistically significant pancreatitis-incidence signal in the trial populations; severe prior pancreatitis history is anticipated to remain an excluded phenotype per the class precedent (§2.4).

Identification. Symptom-prompted — persistent severe upper abdominal pain radiating to back, often with vomiting, often worse with food. Differential: GI AE class (§6.2) typically does not produce severe persistent localized pain — protocol differentiates “GI AE expected at titration” from “pancreatitis-suspect abdominal pain” via persistence, severity, localization, and lipase.

First-line management. Acute persistent severe abdominal pain with vomiting → immediate evaluation, lipase + amylase + CMP + CBC + lipid panel (rule out hypertriglyceridemic pancreatitis), abdominal imaging (CT or MRCP). Discontinue survodutide pending evaluation.

Escalation triggers. Confirmed acute pancreatitis → hospitalization, supportive management. Severity stratification via Ranson / BISAP / APACHE-II.

Discontinuation triggers. Confirmed acute pancreatitis attributable to survodutide (excluding alternative etiology — gallstones, hypertriglyceridemia, alcohol) → permanent discontinuation, transition to alternative therapy if Module 5 indication continues.

6.5 NAION AE class — research-state-pending class-context signal

Anticipated anticipatory framing. Lakhani I et al. Am J Ophthalmol 2025 (PMID 40383360) documented an optic nerve and retinal adverse-event signal class-differentiated within the GLP-1 RA class through a multicenter observational pharmacovigilance study. The Lakhani analysis surfaced a signal associated with semaglutide; the signal was absent for tirzepatide at the same analytic threshold. Survodutide-specific NAION signal characterization will emerge from the SYNCHRONIZE + LIVERAGE Phase 3 safety reporting; Phase 2 trial reporting may be too small for robust NAION signal detection.

Pattern AA precision: NAION signal status for survodutide is research-state-pending as of 2026-05-13. The protocol does NOT generalize the semaglutide NAION signal to survodutide; does NOT assume absence of signal in survodutide; does NOT infer signal direction from absence of detection in Phase 2. The class-context awareness informs clinician-judgment pre-screening for known optic-disc cupping, prior NAION, or unexplained visual symptoms in patients at higher anatomic risk.

Identification. Acute monocular vision loss, typically painless, often altitudinal visual field defect. Optic disc edema on exam in the acute phase. Differential includes giant cell arteritis (arteritic AION, separate entity), retinal vascular occlusion, optic neuritis.

First-line management. Urgent ophthalmology evaluation. Discontinue survodutide pending evaluation. Cross-reference with ESR/CRP to rule out arteritic etiology.

Discontinuation triggers. Confirmed NAION → permanent discontinuation; ophthalmology co-management for fellow-eye monitoring.

6.6 Injection-site AE class

Anticipated anticipatory framing. Injection-site reactions (erythema, induration, pruritus, nodule) are anticipated for any subcutaneous-injectable peptide therapeutic. Site-rotation discipline mitigates. Lipohypertrophy can develop with site-rotation failure.

Identification. Patient-reported or visit-observed. Photograph documentation if reaction is moderate or atypical.

First-line management. Site-rotation reinforcement (abdomen, thigh, upper arm — alternate weekly). Topical hydrocortisone for pruritus.

Discontinuation triggers. Severe / systemic hypersensitivity reaction is the anticipated §2.4 labeled contraindication and triggers permanent discontinuation.

6.7 Hypoglycemia AE class (T2D indication with concurrent insulin or sulfonylurea)

Anticipated anticipatory framing. Survodutide is anticipated not to be hypoglycemia-inducing as monotherapy at therapeutic doses — the GLP-1R-mediated glucose-dependent insulin secretion is protective against hypoglycemia in the absence of concurrent hypoglycemia-inducing agents, and the GCGR-mediated counter-regulatory hyperglycemia mechanism (canonical §6.13.1) provides additional counter-balance. Hypoglycemia risk emerges when survodutide is combined with insulin or sulfonylurea — the standard Module 5 GLP-1 RA class management applies: reduce the dose of the concurrent agent at survodutide initiation.

Identification. Patient-reported hypoglycemia events; CGM data if available.

First-line management. Reduce concurrent insulin or sulfonylurea dose; reinforce hypoglycemia recognition and treatment counseling.

Discontinuation triggers. Hypoglycemia from survodutide is not a discontinuation indication for survodutide; it is a dose-adjustment indication for the concurrent agent.

6.8 Diabetic retinopathy in T2D — rapid HbA1c improvement context

Anticipated anticipatory framing. Rapid glycemic improvement is associated with transient diabetic retinopathy worsening across the diabetes pharmacotherapy class per the SUSTAIN-6 retinopathy-complication signal in semaglutide (Marso 2016 PMID 27633186). The survodutide T2D Phase 2 trial (Blüher 2024 PMID 38095657) included retinopathy event reporting; Phase 3 SYNCHRONIZE-2 obesity + T2D readout will expand the survodutide-specific characterization.

Clinical-use considerations in patients with established diabetic retinopathy: ophthalmologic baseline assessment per §3.7; close monitoring during titration and rapid glycemic improvement.

6.9 Pregnancy on protocol (anticipated CWM and MASH-indication context)

Anticipated anticipatory framing. Pregnancy on protocol is the §8 anticipated discontinuation trigger; the survodutide-specific pharmacokinetic context (approximately six-day elimination half-life; ~30-35 day pharmacokinetic clearance) is documented in §8.4. The Parker D et al. Diabetes Obes Metab 2025 (PMID 40329607) pooled regulatory pregnancy-exposure data anchors the class-level human evidence; survodutide-specific data emerges from Phase 3 program unplanned-pregnancy reporting. Pattern Z calibration anchor 3 framing applies (research-state-leading section structure; standard practice framed as factual, not steering).

First-line management. Discontinue survodutide on pregnancy awareness; obstetrics co-management; the pharmacokinetic clearance window documented for the obstetrics record. Post-pregnancy and post-lactation, re-initiation decision per §1 indication and §2 selection-criteria reapplication.

6.10 Survodutide-specific hepatic transaminase AE class (NEW for survodutide protocol)

Anticipated anticipatory framing. Glucagon-receptor agonism is anticipated to produce transient hepatic transaminase elevation through fatty-acid mobilization into hepatocyte β-oxidation (canonical §6.13.2); the mechanism is parallel to the transaminase patterns observed during accelerated weight loss. The Phase 2 MASH trial (Sanyal 2024 PMID 38847460) reported transaminase normalization or improvement at the dose-responsive efficacy doses, consistent with the MASH-resolution histopathology endpoint. Phase 3 LIVERAGE F2/F3 readout will provide the load-bearing maintenance-period transaminase characterization. Pattern AA precision: the survodutide-specific transaminase pattern is anticipated mechanism-rationale-based monitoring per canonical §6.13.2; it is NOT a labeled warning or labeled contraindication as of 2026-05-13.

Identification. Periodic ALT/AST per §4.5 + §5.3 + §5.5.3 monitoring schedule. Transient titration-period elevation is anticipated. Sustained elevation (e.g., ≥3× upper limit normal sustained at 8-week reassessment) with clinical correlation suggesting progression beyond mechanism-related transient elevation triggers escalation.

First-line management. Periodic ALT/AST every 4-8 weeks during titration and every 12-24 weeks at maintenance. For transient titration-period elevation in MASH-confirmed populations: clinician-judgment on transient-elevation-vs-progression interpretation; anticipated improvement as MASH resolves per the Phase 2 MASH trial pattern; continue dose with closer follow-up. For elevation in non-MASH-etiology baseline: clinician-judgment for the mechanism-related-vs-non-MASH-etiology interpretation; hepatology co-management if interpretation uncertain.

Escalation triggers. Sustained ALT/AST elevation with clinical correlation; jaundice or pruritus suggesting cholestasis; transaminase elevation with INR or bilirubin elevation suggesting hepatic synthetic dysfunction. Hepatology referral; consideration of alternative-etiology workup (viral hepatitis re-screen, drug-induced liver injury workup with concurrent medication review, autoimmune hepatitis workup if clinically suggested).

Discontinuation triggers. Sustained ALT/AST elevation with hepatic synthetic dysfunction (INR / bilirubin elevation) attributable to survodutide after alternative-etiology workup — permanent discontinuation, hepatology co-management. Patient preference for discontinuation given the transaminase pattern is a Pattern Z calibration point — the protocol does not override patient preference.

6.11 Survodutide-specific glycemic-monitoring AE-class-equivalent (NEW for survodutide protocol)

Anticipated anticipatory framing. The GCGR-mediated counter-regulatory hyperglycemia mechanism (canonical §6.13.1) is anticipated to be mechanistically present but not clinically observed at therapeutic doses per the Phase 2 program data (PMID 38330987 obesity; PMID 38847460 MASH; PMID 38095657 T2D — no clinically significant hyperglycemia signal). The mechanism-rationale-based monitoring posture is mechanism-rationale-based confirmation that individual patient response aligns with trial-population data, NOT regulatory-deficit-framed surveillance.

Identification. Baseline + periodic HbA1c / fasting glucose per §4.5 + §5.3 + §5.5.2 monitoring schedule.

First-line management. For unexpected glycemic worsening: clinician-judgment workup including assessment of concurrent agents, dietary changes, infection, other comorbidities; survodutide-mechanism-related glycemic effect at therapeutic doses is not anticipated to be the primary etiology per the Phase 2 program data.

Discontinuation triggers. Sustained unexplained glycemic worsening attributable to survodutide after alternative-etiology workup is anticipated to be rare; clinician-judgment.

6.12 Survodutide-specific catabolic-axis lean-mass-preservation AE-class-equivalent (NEW for survodutide protocol)

Anticipated anticipatory framing. Glucagon-receptor agonism is anticipated to stimulate hepatic amino-acid catabolism and ureagenesis as part of the broader counter-regulatory metabolic program (canonical §6.13.3). Chronic-state implications of survodutide-mediated GCGR engagement for muscle mass, lean body mass, and protein metabolism are research-state-characterized; the NCT06745284 Phase 1 trial of energy expenditure and fatty acid oxidation will provide mechanism-specific data (ACTIVE_NOT_RECRUITING; primary completion 2027-01-08). Phase 3 trial body-composition data per primary publications will expand characterization.

Identification. Body-composition tracking per §3.7.5 + §3.8 + §5.5.4. Lean-body-mass trajectory vs total-weight trajectory; functional strength (hand-grip, sit-to-stand) tracking.

First-line management. Standard weight-management protein intake recommendations (~1.2-1.6 g/kg/day for adults under active weight loss); resistance training adjuncts; lean-body-mass-preservation counseling reinforced at each visit during active weight loss.

Discontinuation triggers. Disproportionate lean-mass loss with clinical functional impairment is anticipated to be rare with appropriate nutritional + resistance training adjuncts; clinician-judgment.

6.13 Worked example — survodutide AE management at anticipated maintenance dose 6.0 mg

A patient (anticipated context: the §1.5 polycondition MASH F2 case at Month 6 maintenance) on survodutide 6.0 mg weekly subcutaneous, presents with anticipated AE-emergence scenarios:

Scenario A — Anticipated Grade 2 nausea with on-trajectory weight loss and improving ALT/AST. Anticipated pattern within the trial-program-typical AE profile at maintenance dose. First-line management: meal-size and meal-composition reinforcement; consider scheduled (not just PRN) ondansetron during the post-injection window. Reassessment at next visit: if Grade 2 nausea remains and patient is on-trajectory for indication targets (weight loss + transaminase improvement reflecting MASH resolution), continue current dose; if Grade 2 nausea is unacceptable to patient (Pattern Z calibration: patient-preference-anchored, not clinician-override), dose-down to 4.8 mg with reassessment at Month 9.

Scenario B — Anticipated sustained ALT/AST elevation 4× ULN at Month 4 maintenance check; INR normal; bilirubin normal; no jaundice; no pruritus. Per §6.10 survodutide-specific transaminase AE class algorithm: clinician-judgment for transient-elevation-vs-progression interpretation. Alternative-etiology workup: viral hepatitis re-screen, concurrent medication review for drug-induced liver injury, alcohol intake review. If alternative-etiology workup negative and clinical correlation supports mechanism-related-vs-MASH-progression interpretation, anticipated continuation at current dose with closer follow-up (4-week reassessment of ALT/AST). FibroScan / VCTE follow-up to track non-invasive fibrosis trajectory. Hepatology co-management for interpretation guidance if uncertain.

Scenario C — Anticipated confirmed acute pancreatitis. Per §6.4: discontinue survodutide; alternative-etiology workup (gallstones, hypertriglyceridemia, alcohol). If alternative etiology ruled out and survodutide-attributable acute pancreatitis is the working diagnosis: permanent discontinuation; transition to non-GLP-1 alternative if Module 5 indication continues.

Scenario D — Anticipated acute painless monocular vision loss; ophthalmology evaluation confirms NAION. Per §6.5: discontinue survodutide; permanent discontinuation given the confirmed NAION; ophthalmology co-management for fellow-eye monitoring. Pattern Z calibration: the NAION signal status for survodutide is research-state-pending; in a confirmed individual event, the management response is alignment with the signal-direction precaution. Module 5 indication continuation: clinician + patient decide on alternative therapy. Tirzepatide cross-class option carries the Lakhani 2025 signal-absent finding at the same analytic threshold; cross-class direction-of-effect for survodutide-discontinuation-then-tirzepatide is not established but is a research-state-favorable consideration. Patient + clinician decide.

Pattern AA precision in §6.13. “Pancreatitis-attributable to survodutide” is precise (alternative etiologies ruled out; temporal association). “Survodutide-specific transaminase pattern” is precise — mechanism-rationale-based monitoring per canonical §6.13.2; NOT a labeled warning. “NAION signal-direction precaution” is precise — research-state-pending for survodutide; signal-direction alignment in confirmed individual events reflects clinician-judgment, not labeled mandate.

7. Plateau and non-response algorithm

7.1 Purpose

Define the structured clinical-decision approach when survodutide’s anticipated primary effect has not met its target (non-response) or has stalled below a clinically meaningful endpoint (plateau). Section 7 is the diagnostic-and-decision branch point: distinguish pseudo-plateau (apparent stall that is in fact normal-trajectory variation) from true plateau (legitimate response stall requiring intervention) and from non-response (insufficient initial effect from the start).

7.2 Pseudo-plateau vs true plateau vs non-response — diagnostic distinctions

Pseudo-plateau. Apparent stall in weight, HbA1c, or hepatic-fat-reduction trajectory that is in fact within normal week-to-week or month-to-month variation, or that reflects body-composition change (lean mass preservation with fat-mass continued loss) rather than total-weight stall, or that occurs in the predictable trial-trajectory pattern (most weight-loss molecules show a deceleration in months 6-9 even on continued effective therapy). Pseudo-plateau is recognized by trajectory-context.

True plateau. Legitimate response stall — patient was responding, then response flattens or reverses. True plateau is recognized by trajectory inflection plus an adequate observation window (typically 2-3 months at stable dose).

Non-response. Insufficient initial effect from the start. Recognized at Month 3-6 on target dose with effect substantially below the trial-program-typical effect for the patient’s phenotype.

7.3 Set-point reset framing

Weight-regulation physiology operates on a defended set-point that the body actively resists changes from. Weight loss into a new set-point window typically requires sustained pharmacologic and behavioral intervention; loss beyond the body’s defended range tends to recruit counter-regulatory responses. True plateau in CWM context is often the body’s defense at a new set-point — not therapeutic failure but biological-equilibrium attainment. The protocol framing in counseling (§10) does not pathologize plateau but reframes it as biological-equilibrium.

Survodutide-specific set-point consideration: the GCGR-mediated energy-expenditure mechanism may modify the adaptive-thermogenesis response during chronic weight loss (canonical §2.3 brown adipose tissue thermogenesis; canonical §6.13.3 catabolic axis); the survodutide-specific set-point trajectory is research-state-incomplete and emerges from Phase 3 program body-composition + energy-expenditure data (NCT06745284 Phase 1 active comparator energy expenditure trial; primary completion 2027-01-08).

7.4 Anticipated decision tree for plateau / non-response

Confirm adherence. Missed doses, injection-technique issues. Confirm via patient interview.
Confirm trajectory-context. Plot the patient’s curve against the trial-program-typical curve for their phenotype (anticipated Phase 2 dose-finding trajectory PMID 38330987 for obesity; anticipated SYNCHRONIZE-1 Phase 3 sponsor topline 16.6% at 76 weeks; anticipated Phase 2 MASH histopathology trajectory PMID 38847460 for MASH F2/F3).
Confirm dose attainment. Is the patient on anticipated target dose 6.0 mg? If not, complete titration; reassess.
Reassess phenotype. Does the patient’s clinical picture support a phenotype the trial program enrolled, or is the patient in an under-represented or out-of-trial phenotype?
If true plateau / non-response confirmed at adequate observation window:
- CWM context: consider transition to tirzepatide (SURMOUNT-1 effect-size approximately −22.5% at 15 mg in non-diabetic obesity; SURMOUNT-5 head-to-head vs semaglutide showed tirzepatide −20.2% vs semaglutide −13.7%); or consider transition to retatrutide (pre-approval; if available through trial-enrollment); or consider intensification of behavioral / nutritional / activity program rather than pharmacologic change.
- T2D context: transition to tirzepatide (SURPASS-2 head-to-head, tirzepatide higher effect); or add SGLT2 inhibitor; or add insulin per ADA/EASD progression algorithm.
- MASH F2/F3 context: semaglutide (FDA-approved for marketing claims for MASH F2/F3 per ESSENCE PMID 40305708) is a within-class alternative with FDA-approved-for-marketing-claims status; resmetirom (FDA-approved for marketing claims for non-cirrhotic F2/F3 MASH per 2024 NDA approval) is a mechanism-class-distinct alternative (THRb-selective agonism). Consider hepatology co-management for further options if survodutide non-response confirmed at MASH F2/F3 indication.
- MASH F4 cirrhosis context: class-comparator semaglutide (Loomba 2023 PMID 36934740 Phase 2 in NASH-related cirrhosis primary fibrosis-improvement endpoint not statistically significant) does NOT provide an established within-class alternative for F4 cirrhosis as of 2026-05-13. Resmetirom is approved for non-cirrhotic F2/F3 only (not F4). Hepatology co-management.
- CV-risk context: SYNCHRONIZE-CVOT readout pending will inform the CV-risk indication context.

7.5 Worked example — survodutide non-responder algorithm anticipated for the §1.5 polycondition MASH F2 case

The 56-year-old male in §1.5, anticipated Month 6 on survodutide 6.0 mg target dose. Anticipated MASH-trajectory non-response scenario: weight loss approximately 6% (modest; in-class range), HbA1c improved from 7.9 to 7.4, but FibroScan stable at 11 kPa (no improvement) and ALT/AST persistently elevated 2× ULN without improvement trajectory.

Algorithm walkthrough.

Step 1 — adherence. Patient reports 100% adherence; prescription audit confirms no gaps.

Step 2 — trajectory-context. Anticipated Phase 2 MASH trajectory at 6.0 mg by Month 6 would include transaminase improvement reflecting MASH resolution; this patient’s transaminase trajectory is non-improving and FibroScan is stable — below the anticipated trajectory.

Step 3 — dose attainment. Patient is on 6.0 mg target dose.

Step 4 — phenotype reassessment. Patient is at the MASH F2 enrollment phenotype per §1.5; phenotype is trial-enrolled and the anticipated trajectory is for MASH resolution by Month 6-12 on 6.0 mg.

Step 5 — MASH F2/F3 non-response context. Decision branches:

5a. Continue current survodutide regimen and extend observation window. MASH histopathology endpoints typically require 48-week trajectory assessment per the Phase 2 MASH trial (Sanyal 2024). Continuing through Month 12 to assess full anticipated MASH-resolution trajectory is one option. Patient + clinician decide.

5b. Transition to semaglutide 2.4 mg for MASH F2/F3 (FDA-approved for marketing claims per ESSENCE PMID 40305708). Semaglutide is the FDA-approved-for-marketing-claims MASH therapy with the published Phase 3 evidence base. Effect-size context per ESSENCE primary publication; FDA-approved-for-marketing-claims regulatory status. Patient prior 14-month semaglutide 1.0 mg experience supports tolerability; transition to the higher semaglutide MASH dose (2.4 mg) is a within-class alternative with FDA-approved-for-marketing-claims regulatory state.

5c. Transition to resmetirom (FDA-approved for marketing claims for non-cirrhotic F2/F3 MASH per 2024 NDA approval). Mechanism-class-distinct alternative (THRb-selective). Phase 3 follow-on real-world evidence and extension data per Noureddin M et al. Aliment Pharmacol Ther Dec 2025 (PMID 41127972). Patient + clinician decide.

5d. Transition to tirzepatide (anticipated MASH Phase 3 program in development; not FDA-approved for marketing claims for MASH as of 2026-05-13). Tirzepatide is FDA-approved for marketing claims for CWM and T2D, with Phase 2 MASH NEJM evidence base (Loomba 2024 SYNERGY-NASH PMID 38856224); MASH Phase 3 in development. For this MASH F2 patient, transitioning to tirzepatide would be off-label for the MASH indication (CWM + T2D label-supported; MASH off-label). Patient + clinician decide with the off-label framing per §10.6.

Pattern Z calibration anchor applied at §7.5. The decision among 5a / 5b / 5c / 5d is patient-anchored, not clinician-mandated. The counseling beats (§10) present the trial-program-anchored effect-size estimates and regulatory-status framing for each option without steering. Each option’s trade-offs (cost, AE-profile, regulatory status, FDA-approved-for-marketing-claims vs off-label, trial-enrollment alternatives) are presented; the clinician-patient decision is patient-preference-driven within the medically reasonable options. The shared-decision-making invitation closes the conversation.

Pattern AA precision in §7.5. Every regulatory claim is precise per the §10.5 Pattern AA.marketing-claims framing: semaglutide is FDA-approved for marketing claims for MASH F2/F3 (ESSENCE 2025); resmetirom is FDA-approved for marketing claims for non-cirrhotic F2/F3 MASH (2024 NDA); tirzepatide is FDA-approved for marketing claims for CWM and T2D, NOT for MASH as of 2026-05-13 (off-label for MASH); survodutide is pre-FDA-approval-for-marketing-claims, with FDA Breakthrough Therapy designation for MASH (regulatory-procedural status, not approval); retatrutide is pre-FDA-approval-for-marketing-claims.

8. Discontinuation and tapering

8.1 Purpose

Define when to stop survodutide, how to taper if tapering is indicated, and how to frame post-discontinuation expectations — particularly the weight-regain trajectory in CWM indications and the MASH-resolution-durability trajectory in MASH indications. Section 8 is the symmetric counterpart to §4 (initiation): just as initiation has anticipatory framing for AE and adherence, discontinuation has anticipatory framing for the post-discontinuation period and for the patient-and-clinician decision about whether and when to re-initiate.

8.2 When to discontinue — anticipated discontinuation triggers

Anticipated discontinuation is indicated when one of the following emerges:

Confirmed contraindication discovery (e.g., new MTC diagnosis, new MEN-2 family-history identification, new pregnancy in CWM-indication or MASH-indication context). §2.4 anticipated hard contraindications are immediate-discontinuation triggers.
Severe AE attributable to survodutide (confirmed acute pancreatitis, confirmed NAION, severe hypersensitivity reaction; survodutide-specific sustained hepatic transaminase elevation with synthetic dysfunction). §6 AE-class-specific discontinuation triggers.
Indication remission or resolution (T2D HbA1c sustained below target with weight stable in some patients; MASH histologic resolution sustained — rare but documented in the GLP-1 RA MASH literature).
Patient preference. Patient-anchored discontinuation decision is legitimate; the protocol’s role is to inform the post-discontinuation expectations and the re-initiation pathway.
Cost / access barriers. A documented practice-level reality particularly for pre-approval compound access. Pattern Z calibration anchor 1+2 (compounded vs FDA-approved-for-marketing-claims with pre-approval-compound adaptation) framing applies in §10 — present the cost / access reality factually, not as steering.
Pre-conception planning for reproductive-age patients on CWM or MASH indication: discontinuation with approximately 30-35-day pharmacokinetic clearance window plus the anticipated 2-month pre-conception window per the §8.4 arithmetic.

8.3 How to taper — anticipated survodutide-specific tapering considerations

For survodutide once approved per CWM or MASH indication: anticipated pharmacokinetic tapering (step-down dosing) is not pharmacologically required — the half-life-driven pharmacokinetic washout occurs at fixed kinetics regardless of taper schedule (approximately six-day elimination half-life; ~30-35 day pharmacokinetic clearance). However, anticipated gradual dose reduction is the recommended pattern for two reasons:

Weight-regain trajectory smoothing. Abrupt discontinuation produces faster weight-regain than gradual reduction; gradual reduction allows behavioral adaptation.
AE-class symmetry. Some patients experience appetite-rebound or GI-pattern shifts on abrupt discontinuation; gradual reduction attenuates these. Survodutide-specific consideration: the GCGR-mediated hepatic mechanism may produce transient hepatic-state shifts on discontinuation (research-state); gradual reduction allows hepatic-pattern adaptation in parallel with weight and metabolic adaptation.

Anticipated taper pattern for survodutide CWM or MASH indication: 6.0 mg → 4.8 mg for 4 weeks → 3.6 mg for 4 weeks → 2.4 mg for 4 weeks → discontinue. Total taper period approximately 12 weeks. This is anticipated clinician-judgment within the post-approval label framework; the post-approval FDA label may permit abrupt discontinuation. Pattern AA precision: “anticipated clinician-judgment within anticipated label,” not “label-recommended” because the survodutide-specific FDA label is not yet published as of 2026-05-13.

8.4 Pre-conception washout arithmetic — survodutide pharmacokinetic context

Survodutide has an elimination half-life of approximately six days (canonical §1.3). Approximately 5 half-lives are required for >95% pharmacokinetic clearance — approximately 30-35 days. The anticipated FDA label for survodutide is anticipated to specify discontinuation approximately 2 months before a planned pregnancy per the GLP-1 RA class precedent (semaglutide label recommends 8-week pre-conception washout per the ~1-week half-life arithmetic and conservative-clinical-margin recommendation). The survodutide-specific 30-35-day pharmacokinetic clearance plus ~25-day margin gives the anticipated 2-month (~8-week) pre-conception window.

This anticipated 2-month pre-conception window is the operational counseling beat for reproductive-age patients on anticipated survodutide CWM or MASH indication — §10 counseling beats anchor to this arithmetic with Pattern Z calibration anchor 3 (pregnancy planning) precision.

8.5 Post-discontinuation weight-regain framing

The class-level data on post-GLP-1-RA-discontinuation weight regain anchor to the STEP-4 trial (Rubino 2021 PMID 33755728 — STEP-4 maintenance trial demonstrated approximately two-thirds of lost weight regained by 12 months post-discontinuation of semaglutide) and to the SURMOUNT-4 trial (tirzepatide demonstrated approximately 14% body weight regain on withdrawal vs continued treatment over 36→88 weeks). The mechanism — set-point physiology and the defended-weight biology described in §7.3 — predicts that without pharmacologic support, the body’s counter-regulatory responses re-establish a higher equilibrium.

Survodutide-specific post-discontinuation framing: survodutide-specific post-discontinuation data are research-state-incomplete as of 2026-05-13; the SYNCHRONIZE Phase 3 program extension data per primary publications will inform the survodutide-specific weight-regain and MASH-durability trajectory. The mechanism-rationale-based anticipation is that GLP-1R-mediated appetite suppression and GCGR-mediated thermogenesis discontinuation produce weight-regain consistent with the class-level pattern; the GCGR-mediated hepatic mechanism discontinuation may produce a distinct hepatic-state trajectory (research-state-incomplete; LIVERAGE Phase 3 long-term outcomes will inform).

The protocol framing in counseling (§10) does not pathologize weight regain post-discontinuation; it frames the regain trajectory as the expected biological response, the same way pre-treatment counseling framed the appetite-suppression mechanism as the biological intervention.

8.6 Re-initiation pathway

A patient who discontinued and is considering re-initiation: typically re-titration from the starting dose (0.6 mg weekly) is the recommended pattern — the tolerability re-priming is equivalent to initial titration; abrupt re-initiation at the prior target dose is not recommended due to GI AE recurrence risk. §4 titration applies. Indication confirmation per §1, selection-criteria re-screening per §2, and pre-treatment workup refresh per §3 if the discontinuation period exceeded approximately 12 months or if any new comorbidity has emerged.

8.7 Worked example — survodutide anticipated discontinuation scenarios

Scenario A — anticipated pre-conception planning. A 34-year-old female on anticipated survodutide 6.0 mg for CWM indication (post-approval anticipated context), Month 14 on target dose, has lost approximately 18% of starting weight and is planning conception in approximately 6 months. Counseling beat: discuss the anticipated 2-month pre-conception window per anticipated label arithmetic; plan taper start approximately 5 months from now (12-week taper period, then approximately 8-week post-discontinuation pharmacokinetic-and-margin window). Pattern Z calibration anchor 3 applies — pregnancy-planning counseling presents Parker 2025 (PMID 40329607) class-level human pregnancy-exposure data first (research-state-leading), then pharmacokinetic facts (~6-day half-life; ~30-35 day clearance), then anticipated label recommendation (anticipated 2-month pre-conception window), then post-discontinuation weight-regain trajectory.

Scenario B — patient-preference discontinuation at Month 18. A 58-year-old male on anticipated survodutide 6.0 mg, has lost approximately 16% of starting weight and stabilized at the new weight for the last 4 months; reports tolerable but consistent mild GI AE profile and wishes to discontinue. Counseling beat: discuss class-level STEP-4 / SURMOUNT-4 trajectory data — approximately two-thirds of lost weight regained by 12 months post-discontinuation across the class; survodutide-specific post-discontinuation data are research-state-incomplete; re-initiation pathway is available. Anticipated taper: 6.0 → 4.8 → 3.6 → 2.4 → off over approximately 12 weeks. Post-discontinuation monitoring at Month 3, 6, 12.

Scenario C — confirmed acute pancreatitis (per §6.4). Permanent discontinuation. No taper — abrupt discontinuation appropriate given AE-attributable etiology. Transition to non-GLP-1 alternative per indication.

Scenario D — new pregnancy on protocol. A 30-year-old female on anticipated survodutide 6.0 mg discovers pregnancy at approximately 5 weeks gestation. CWM-indication survodutide is anticipated to be a labeled contraindication in pregnancy (anticipated per class precedent). Immediate discontinuation. Obstetrics co-management; the pharmacokinetic clearance window (~30-35 days, with first-trimester exposure already occurred) documented for the obstetrics record. Pattern Z calibration anchor 3: Parker 2025 (PMID 40329607) pooled class-level data is the load-bearing human evidence; survodutide-specific pregnancy-exposure data within the pooled dataset is sparse given pre-approval status; counseling presents the research-state-leading framing. Post-pregnancy and post-lactation, re-initiation decision per §1 indication and §2 selection-criteria reapplication.

Scenario E — sustained ALT/AST elevation with hepatic synthetic dysfunction (per §6.10). Permanent discontinuation. Hepatology co-management. Transition to non-survodutide alternative per indication; the survodutide-specific transaminase + synthetic-dysfunction pattern attributable after alternative-etiology workup is anticipated to be rare per the Phase 2 program safety profile; specific Phase 3 incidence per primary publications.

Pattern Z calibration anchor 3 precision in §8.7. Pregnancy-planning counseling leads with Parker 2025 human pregnancy-exposure data (PMID 40329607), then survodutide-specific pharmacokinetic facts, then anticipated label recommendation, then post-discontinuation weight-regain trajectory — facts that the patient uses to make her reproductive-and-treatment-planning decision. The protocol does not steer the patient toward continued pharmacotherapy by emphasizing weight-regain risk, nor toward discontinuation by emphasizing pregnancy-exposure risk. Both facts are presented; the patient decides. Animal data + class-level contraindication framing is relegated to scoped factual context AFTER the research-state lead, not used as section-opening framing.

9. Combination rules

9.1 Purpose

Define what stacks with survodutide, what is anticipated to be contraindicated in combination, and the rationale for each combination category. Section 9 is the protocol’s bridge to Module 5.12 Combination Protocols and to the lean-mass-stack protocols (M5.5 Tesamorelin / AOD-9604; M5.6 Lean Mass / CJC-Ipamorelin / MOTS-c). For survodutide in pre-approval state, combination considerations operate under the anticipated post-approval clinical-use framework plus the active-trial-enrollment regulatory framework.

Pattern W cross-section consistency applies: every combination in this section is reconciled with §2 (a combination cannot include an agent that triggers an anticipated contraindication), §6 (combinations cannot mask or exacerbate AE-class concerns), and §10 (counseling beats for combinations are anchored to Pattern Z calibration anchors).

9.2 Within-Module-5 anticipated combinations

The principal within-Module-5 anticipated combinations involve combining mechanism classes within the metabolic axis:

Survodutide + SGLT2 inhibitor (T2D indication context). Anticipated class-additive HbA1c and cardiovascular / kidney benefits; commonly co-prescribed in T2D + CKD or T2D + ASCVD context per Module 5 class precedent. Mechanism rationale: SGLT2 inhibitor adds glucose-osmotic-diuretic and ketogenesis-modulating effects. The combination is anticipated to be well-supported by class-level individual-agent CVOT and KOOT data once survodutide is approved.
Survodutide + insulin (T2D advanced). Anticipated common in T2D with progressed beta-cell failure where survodutide monotherapy is insufficient. §6.7 hypoglycemia management applies; concurrent insulin dose typically reduced approximately 20% at GLP-1 RA initiation per class precedent. Survodutide-specific consideration: the GCGR-mediated counter-regulatory hyperglycemia mechanism may modify the insulin-dose-reduction calculus modestly relative to single-GLP-1R agonist + insulin combination; mechanism-rationale-based clinician-judgment with close glycemic monitoring.
Survodutide + DPP-4 inhibitor: not anticipated to be indicated. Mechanistic overlap (DPP-4 inhibitor preserves endogenous GLP-1; redundant with exogenous GLP-1 RA component) makes the combination not clinically additive per class precedent. Avoid co-prescribing.
Survodutide + GLP-1 RA monotherapy (semaglutide, liraglutide, dulaglutide, exenatide, tirzepatide, oral non-peptide GLP-1R agonists). Anticipated NOT indicated. Within-class redundancy with additive AE profile and no demonstrated additive benefit. Transition between agents, not co-administration.
Survodutide + retatrutide or other dual/triagonist class. Anticipated NOT indicated. Within-class redundancy. Transition between agents, not co-administration.
Survodutide + amylin analog (cagrilintide / CagriSema-context). Mechanism rationale: amylin co-released with insulin in physiologic glucose response; amylin analog modulates gastric emptying and central satiety. Combination with survodutide is research-state-unstudied as of 2026-05-13; no dedicated trial combining survodutide + cagrilintide exists. CagriSema (Novo Nordisk fixed-combination semaglutide + cagrilintide) is a different combination class. Anticipated clinical-judgment posture pending dedicated combination evidence base.
Survodutide + resmetirom (MASH context). Mechanism-class-distinct combination — THRb-selective agonism + GLP-1/glucagon dual agonism. Mechanism rationale: differential mechanism pathways may support additive MASH benefit. Combination is research-state-unstudied as of 2026-05-13; no dedicated trial combining survodutide + resmetirom exists. Clinician-judgment posture for advanced MASH F2/F3 non-response cases pending dedicated combination evidence base. Hepatology co-management.

9.3 Cross-Module anticipated combinations — lean-mass and body-composition stacks

Cross-Module combinations involve adding a peptide outside the GLP-1 / glucagon / GIP / amylin metabolic-axis family to address a complementary clinical objective — most commonly lean-mass preservation during weight loss. Survodutide-specific consideration: the GCGR-component catabolic-axis effect (canonical §6.13.3) may make lean-mass-preservation adjuncts more clinically informative for survodutide than for single-GLP-1R agonist regimens.

Survodutide + CJC-1295 / Ipamorelin (GH secretagogue stack). Mechanism rationale: CJC-1295 (GHRH analog) plus Ipamorelin (GH secretagogue) elevates endogenous growth hormone pulsatility, supporting lean-mass preservation during caloric deficit. Module 5.6 Lean Mass canon documents the M5.6 v3 stack with phenotype targeting, monitoring (IGF-1 anchored), and AE-class considerations. Combination with survodutide is research-state for the survodutide-specific context but inherits the M5.6 v3 stack framework. Pattern N.1 applies: CJC-1295 and Ipamorelin are peptides.
Survodutide + MOTS-c (mitochondrial peptide). Mechanism rationale: MOTS-c is a mitochondrially-encoded peptide with metabolic-regulator activity in preclinical models. Trial-program status: limited human Phase 1/2 data; clinician judgment within Module 5.6 stack framing. Pattern AA precision: do not state “approved” for an investigational peptide.
Survodutide + Tesamorelin (FDA-approved-for-marketing-claims for HIV-associated lipodystrophy; off-label for visceral adiposity in non-HIV context). Mechanism rationale: Tesamorelin (GHRH analog) reduces visceral adipose tissue; in combination with survodutide-mediated weight loss, visceral-adiposity-targeted effects may be additive. Module 5.5 Tesamorelin canon. Pattern AA precision: the off-label-for-non-HIV-visceral-adiposity framing is explicit, not implicit.
Survodutide + GHK-Cu (skin / connective-tissue peptide). Module 5.7 (skin-elasticity, post-weight-loss skin tone). Pattern V direction-of-effect: GHK-Cu trial-program data are limited.

9.4 Anticipated contraindicated combinations

Survodutide + DPP-4 inhibitor (§9.2 — anticipated not contraindicated by safety; anticipated not clinically additive and not indicated by class precedent convention).
Survodutide + concurrent GLP-1 RA monotherapy (semaglutide, liraglutide, dulaglutide, exenatide, tirzepatide) — anticipated within-class redundancy; transition between agents, not co-administration.
Survodutide + concurrent dual/triagonist class — anticipated within-class redundancy.
Survodutide + sulfonylurea at full sulfonylurea dose (relative — anticipated excess hypoglycemia risk; sulfonylurea should be reduced or discontinued at survodutide initiation per §6.7).
Survodutide + agents that severely delay gastric emptying (relative — additive gastric-emptying delay may worsen GI AE profile).

9.5 Worked example — survodutide anticipated combination scenarios for the §1.5 polycondition MASH F2 case

Scenario A — survodutide 6.0 mg + SGLT2 inhibitor (T2D + MASH polycondition context). Patient’s T2D + CKD-borderline (eGFR 71; UACR 28) profile supports SGLT2 inhibitor (empagliflozin or dapagliflozin) for additive HbA1c, CV, and kidney benefit per Module 5 polycondition standard regimen. Combination with survodutide is anticipated to be well-supported by class-level individual-agent data; the SGLT2 + GLP-1/glucagon-dual combination is research-state-unstudied as a dedicated combination trial but is anticipated to inherit the SGLT2 + GLP-1 RA class precedent. Monitoring: eGFR at 2 weeks post-SGLT2 initiation, then quarterly per §5. Pattern V direction-of-effect: combination is anticipated effect-additive on HbA1c, kidney composite, and CV events per individual-agent data.

Scenario B — survodutide 6.0 mg + CJC-1295 / Ipamorelin lean-mass stack (M5.6 v3). Patient’s BMI 33 with anticipated weight loss + the survodutide GCGR-component catabolic-axis consideration supports the M5.6 v3 stack for lean-mass preservation. Add M5.6 v3 stack per the M5.6 protocol with IGF-1 monitoring and GH-secretagogue-class AE awareness. Monitoring: DEXA at 3 and 6 months on stack to track lean-mass trajectory; IGF-1 quarterly. Pattern Z calibration anchor 5 (off-label / extrapolation transparency) applies — counseling beat states explicitly that CJC-1295 and Ipamorelin are not FDA-approved for marketing claims for this indication and that the combination is supported by mechanism rationale plus M5.6 v3 clinical-practice cohort, not by Phase 3 RCT data.

Scenario C — survodutide + semaglutide concurrent (contraindicated within-class). Patient seeking dual-agent metabolic intensification. Counseling beat: combination not indicated — these are within-class redundant agents. Transition between them (§7 non-response algorithm) is the appropriate decision, not co-administration. Effect-size context: for this patient, the §7.5 decision tree applies — continue survodutide vs transition back to semaglutide 2.4 mg for MASH per ESSENCE vs alternative options.

Scenario D — survodutide + resmetirom (research-state MASH combination). For advanced MASH F2/F3 non-response cases, the survodutide + resmetirom mechanism-class-distinct combination is research-state-unstudied as a dedicated trial. Clinician-judgment posture with hepatology co-management. Counseling beat: explicit research-state-incomplete framing; combination not anchored to Phase 3 RCT data; informed-consent acknowledgement.

Pattern W cross-check at §9.5. Each combination above is reconciled with §2 (no patient enters a combination with an anticipated contraindicated agent), §6 (combination AE-management does not mask or substitute for individual-agent AE-management algorithms), and §10 (counseling beats for combinations are Pattern Z calibration-anchor-compliant).

10. Patient counseling beats (Pattern Z calibration-anchor-compliant)

10.1 Purpose

Define the survodutide protocol’s patient-counseling content — the conversations the clinician has with the patient at each protocol phase under the pre-approval-state framing. Section 10 is the operational anchor for Pattern Z (cumulative-tone calibration), Pattern R (lead-framing calibration), Pattern AA (regulatory-claim precision including the FDA-approved-for-marketing-claims discipline), Pattern Z.injection-framing (no daunting/scary/intimidating language for self-injection mechanics per Dr. Gross 2026-05-13 directive), and Pattern Z.research-precision (no “highly experimental” / “fringe” / “unproven” bias vocabulary; lead with research base).

The five Pattern Z calibration anchors from /Internal/Module-5-Pipeline/pattern-z-calibration-anchor.md apply, with survodutide-specific adaptations: Anchor 5 (off-label / extrapolation transparency) is the dominant calibration surface for survodutide today because of the pre-approval state; Anchor 2 (compounded counseling) operates under pre-approval-compound adaptation (NOT post-approval 503A/503B shortage-period framing).

10.2 Initiation conversation (§4 anchor)

The initiation conversation occurs at the pre-treatment workup completion / §4 initiation visit. Required counseling beats for survodutide:

What survodutide is (Anchor 1 + Pattern Z.research-precision). “Survodutide is a GLP-1 / glucagon dual receptor agonist — a peptide therapeutic that engages two receptors: the GLP-1 receptor, which mediates appetite suppression and gastric emptying delay similar to semaglutide and tirzepatide, and the glucagon receptor, which mediates hepatic fatty-acid oxidation and brown adipose tissue thermogenesis. The dual-receptor mechanism class is mechanistically distinct from single-GLP-1R agonists like semaglutide and from GLP-1/GIP coagonists like tirzepatide. Survodutide is in Phase 3 clinical development — the Phase 2 evidence base is peer-reviewed published in NEJM, Lancet Diabetes Endocrinol, and Diabetologia (PMIDs 38847460, 38330987, 38095657, 38857788); Phase 3 SYNCHRONIZE obesity program reached primary completion in 2025-2026 with the SYNCHRONIZE-1 sponsor topline disclosed in April 2026 (approximately 16.6% body-weight reduction at 6.0 mg vs placebo at 76 weeks); peer-reviewed Phase 3 primary publications are pending. FDA Breakthrough Therapy designation for MASH has been granted, which is a regulatory pathway designation that supports expedited FDA review of the development data — it’s not FDA approval, but it reflects the FDA’s evaluation that the early survodutide data showed substantial improvement potential.”
What it does for the patient’s anticipated indication (Anchor 1, Anchor 4). Expected effect-size with Phase 2 + Phase 3 sponsor-topline trial-anchor precision; comparator framing if patient has alternative-class options.
The titration schedule (§4). Anticipated 16-24 week titration; slow-titration option; the patient is informed that the titration timeline is adjustable to their tolerability.
The AE profile expected at each titration step (§6 GI class anticipatory framing). Nausea is anticipated, typically attenuates, management strategies — non-pharmacologic first, ondansetron PRN second. Reassurance that AE-emergence is anticipated.
Survodutide-specific titration-period monitoring beat (§4.5). Anticipated transient hepatic transaminase elevation during titration in some patients per mechanism rationale; baseline ALT/AST documented; periodic monitoring during titration; trajectory anticipated to improve in MASH-confirmed populations as MASH resolves.
The pre-conception planning beat for reproductive-age patients (Anchor 3). Parker 2025 (PMID 40329607) pooled regulatory pregnancy-exposure data leads; pharmacokinetic facts (~6-day half-life); anticipated 2-month pre-conception window per class precedent; post-discontinuation weight-regain trajectory; re-initiation pathway.
Cost / access realities and the pre-approval-state framing (Anchor 2 with pre-approval-compound adaptation). Present the pre-approval-state options factually: trial enrollment, investigational-supply off-label use, compounded preparations (with §10.3 framing), or anticipated post-approval availability.
Self-injection mechanics (Pattern Z.injection-framing). Standard subcutaneous-injection routine; site-rotation; technique-learnable through standard injection training. NOT framed as daunting, scary, or intimidating.
What the patient signals back if any concern emerges (escalation pathway). Symptoms warranting in-person evaluation within 48 hours.

10.3 Compounded survodutide and pre-approval-supply counseling (Anchor 1 + Anchor 2 with pre-approval-compound adaptation)

The compounded survodutide and pre-approval-supply counseling beat is the most frequently Pattern Z-violation-prone conversation in the pre-approval-state Module 5 protocols, because the regulatory framing differential between compounded preparations under pre-approval regulatory conditions and the anticipated post-approval-formulation can easily slide into steering language. Pattern Z calibration anchor 2 framing with pre-approval-compound adaptation applies (parallels Retatrutide protocol §10.3 framing; NOT post-approval 503A/503B shortage-period framing).

Pattern Z compliant framing. Open with what compounded survodutide IS where it appears in clinical practice: a custom-prepared survodutide preparation produced by a compounding pharmacy, typically delivered as a lyophilized vial requiring reconstitution with bacteriostatic water and measured-dose drawing technique with insulin syringe; available in jurisdictions where compounding pharmacies are licensed to compound peptide therapeutics. The pre-approval-compound regulatory landscape operates under different dynamics than the post-FDA-approval shortage-driven 503A/503B framework that applied to compounded semaglutide and tirzepatide during 2022-2024 shortage periods. What the anticipated post-approval Boehringer Ingelheim formulation IS (once approved): standardized concentration, manufacturer-validated stability, anticipated subcutaneous pre-filled syringe or pre-filled pen presentation per the Phase 1 formulation crossover studies (NCT06772532, NCT07071974, NCT07221591, NCT07407348, NCT07413913).

Pattern Z compliant comparison. Both options anticipate delivery of survodutide. The clinical considerations that differ:

Formulation standardization. Anticipated post-approval Boehringer Ingelheim formulation: standardized concentration, manufacturer-validated stability. Compounded preparations under pre-approval conditions: variable depending on compounding pharmacy quality and protocols; the patient and clinician select a pharmacy with documented quality control. Pattern AA precision: the formulation differential is factual, not steering.
Regulatory framework distinction (pre-approval-specific). The 503A (state-licensed pharmacies compounding to individual prescriptions; oversight via state boards of pharmacy) and 503B (FDA-registered outsourcing facilities compounding for office-stock and patient prescriptions; oversight via FDA cGMP inspection) regulatory frameworks generally require that the active pharmaceutical ingredient (API) be listed on the FDA’s approved bulk drug substances list, OR be used in compounding of an approved drug. Survodutide API listing status differs from semaglutide and tirzepatide because survodutide is pre-FDA-approval; FDA-declared shortage status (which has applied to FDA-approved drugs during periods of high demand) is not applicable to a pre-approval compound. The regulatory landscape for compounded pre-approval peptides operates under different dynamics than the regulatory landscape for compounded FDA-approved-formulation drugs; specific 503A and 503B eligibility for survodutide API depends on the FDA’s bulk drug substances listing decisions and the compounding pharmacy’s regulatory compliance status. Clinical-practice acquisition of compounded survodutide pre-approval is a different regulatory animal than post-approval shortage-driven compounded acquisition; it is not 503A/503B compounding of an FDA-approved drug.
Quality criteria clinicians evaluate. Sterility testing per USP <797> (sterile compounding) and <800> (hazardous drugs) standards; certificate of analysis per batch (peptide content, purity, residual solvents, endotoxin); state-licensure or FDA-outsourcing-facility registration verification; cold-chain shipping documentation.
Cost and access. Compounded: typically lower out-of-pocket cost during the pre-approval period; access varies by jurisdiction and compounding pharmacy. Anticipated post-approval formulation: pricing not yet established; insurance coverage will be determined by payer formularies post-approval.
Clinical-data anchor. Both options anticipate delivery of survodutide; the trial-program effect-size data (Phase 2 and Phase 3 SYNCHRONIZE + LIVERAGE programs) were/are generated with the Boehringer Ingelheim investigational supply. Compounded-preparation effect-size expectations are extrapolated from the investigational-supply trial data with the formulation-variation considerations above.

Patient-counseling beat (verbatim-aligned to Pattern Z calibration anchor 2 with pre-approval-compound adaptation): “Compounded survodutide is a real clinical option that some patients access during this pre-approval period. The operational differences from the Boehringer Ingelheim investigational supply are real — different format that requires reconstitution, different oversight pathway, and the pre-approval regulatory landscape operates differently from the FDA-approved-formulation landscape that emerged for compounded semaglutide and tirzepatide during their shortage periods. If you’re considering compounded survodutide, let’s review the specific compounding pharmacy’s quality practices — sterility testing, certificate of analysis, accreditation — and walk through reconstitution training together. That’s how the decision gets made well.”

Pattern Z.research-precision applied to §10.3. The counseling beat does NOT use “highly experimental,” “fringe,” “unproven,” “risky,” or similar bias vocabulary. The framing leads with what compounded survodutide IS (real clinical option used by some patients during the pre-approval period) and presents the operational and regulatory considerations factually. Pattern Z.injection-framing applied: reconstitution training and self-injection mechanics are framed as a learnable technique; not as daunting or scary.

10.4 Pregnancy-planning conversation (Anchor 3)

For reproductive-age patients on anticipated survodutide CWM or MASH indication (post-approval anticipated context). The conversation LEADS with human pregnancy-exposure research-state data, not with PK arithmetic or label recommendation — this lead-framing discipline is the core of canonical Anchor 3.

Human pregnancy-exposure data — Parker 2025 (PMID 40329607). Pooled review of unplanned pregnancies from FDA- and EMA-submitted GLP-1 RA regulatory clinical trials (semaglutide, liraglutide, dulaglutide, and class-related compounds). Incidence of congenital abnormalities appears relatively low in this pooled dataset; sample size limited; exposures from unplanned-pregnancy contexts. Prospective planned-pregnancy exposure data is research-state-incomplete; authors call for prospective pregnancy registries. Survodutide-specific pregnancy-exposure data within this pooled dataset is sparse given the pre-approval status; Phase 3 trial-population unplanned-pregnancy event reporting will add survodutide-specific data as readouts publish.
Pharmacokinetic facts (post-research-state-lead). Survodutide half-life approximately 6 days; approximately 5 half-lives (~30-35 days) for >95% pharmacokinetic clearance.
Anticipated label recommendation. Anticipated 2-month pre-conception window per class precedent (semaglutide 8-week pre-conception window per Wegovy/Ozempic label is the class precedent).
Animal data context. Reproductive toxicity studies in animals informed the class-level pregnancy precautions. Animal data does not always translate to human teratogenicity profile. Parker 2025 human pooled data is the load-bearing human evidence anchor.
Post-discontinuation weight-regain trajectory. Class-level STEP-4 / SURMOUNT-4 data — approximately two-thirds of lost weight regained by 12 months post-discontinuation; survodutide-specific data research-state.
The patient’s reproductive-planning decision is patient-anchored. Some patients on protocol plan conception within the next 1-2 years; some plan conception within the next decade; some are not planning conception at all but want awareness of the protocol-discontinuation arithmetic in case planning changes. Facts presented; timing decision patient-anchored.
Re-initiation pathway. Post-pregnancy and post-lactation, re-initiation per §8.6 if indication and selection criteria are met.

10.5 Comparator conversation (Anchor 4) — multi-dimensional fact presentation

For patients comparing survodutide to within-class or class-comparator alternatives. Pattern Z calibration anchor 4 framing requires multi-dimensional fact presentation; single-dimension comparison (weight magnitude alone) is the anti-anchor that fails Pattern Z.

For patient question: “How does survodutide compare to semaglutide for MASH?”

MASH efficacy magnitude (Pattern V trial-anchored). Phase 2 MASH for both: survodutide Sanyal 2024 NEJM (PMID 38847460; n=295) — 62% MASH resolution at 6.0 mg vs 14% placebo at 48 weeks; semaglutide ESSENCE Phase 3 (Sanyal 2025 NEJM PMID 40305708) — primary endpoints met per FDA approval for marketing claims for MASH F2/F3 in 2025. Note the same first-author Sanyal AJ for both papers; the two trials are distinct (survodutide Phase 2 vs semaglutide Phase 3) and were published one year apart. Survodutide LIVERAGE F2/F3 Phase 3 readout pending 2031-12.
MASH F4 cirrhosis evidence base. Semaglutide Loomba 2023 Phase 2 in NASH-related cirrhosis (PMID 36934740; n=71) — primary fibrosis-improvement endpoint not statistically significant in F4 cirrhosis. Survodutide LIVERAGE-Cirrhosis F4 Phase 3 readout pending 2029-06 — the first Phase 3 readout planned for any GLP-1 / glucagon dual agonist in compensated cirrhosis.
CWM efficacy magnitude. SYNCHRONIZE-1 sponsor topline 16.6% at 76 weeks (peer-reviewed publication pending) is similar to STEP-1 semaglutide ~14.9% at 68 weeks (Wilding 2021); below SURMOUNT-1 tirzepatide max-tolerated-dose ~−20.9% (TR estimand, PRIMARY ITT) / ~−22.5% (efficacy estimand sub-analysis) at 72 weeks (Jastreboff 2022 PMID 35658024); SURMOUNT-5 head-to-head at week 72 showed tirzepatide −20.2% vs semaglutide −13.7% (Aronne 2025).
Cardiovascular outcomes evidence base. SELECT (Lincoff 2023 NEJM PMID 37952131) for semaglutide CV-risk-reduction in non-diabetic obesity + established CVD (MACE HR 0.80, 95% CI 0.72-0.90); SYNCHRONIZE-CVOT for survodutide CV outcomes (ACTIVE_NOT_RECRUITING; primary completion 2026-05-01).
Regulatory status. Semaglutide is FDA-approved for marketing claims for T2D (Ozempic/Rybelsus), CWM (Wegovy), CV-risk reduction in adults with obesity + established CVD without diabetes (per SELECT 2024 label expansion), CKD risk reduction in T2D (per FLOW 2025 label expansion), and MASH F2/F3 (per ESSENCE 2025 label expansion). Survodutide is pre-FDA-approval-for-marketing-claims as of 2026-05-13; FDA Breakthrough Therapy designation for MASH (regulatory-procedural status, not approval).
Mechanism class. Single GLP-1R for semaglutide; GLP-1 / glucagon dual for survodutide. The GCGR component is mechanism-class-distinct and underlies the hepatic-fat-oxidation mechanism for MASH and the thermogenesis component for energy expenditure.
MASH F-stage scope. Semaglutide FDA-approved for marketing claims for non-cirrhotic F2/F3 MASH per ESSENCE; survodutide LIVERAGE F2/F3 Phase 3 in F2/F3 plus LIVERAGE-Cirrhosis F4 Phase 3 in compensated cirrhosis. Survodutide is the first GLP-1 / glucagon dual agonist with a Phase 3 readout planned in compensated cirrhosis.
GI tolerability profile. Both anticipated GI-dominant AE profile; survodutide-specific GCGR-component AE classes (transaminase, glycemic-monitoring, catabolic-axis) are mechanism-class-distinct.
Ophthalmologic class-context. NAION signal documented for semaglutide per Lakhani 2025 (PMID 40383360); signal absent for tirzepatide at the same analytic threshold; survodutide-specific signal status research-state-pending.
Route / platform availability. Semaglutide: SC injection (Wegovy/Ozempic) + oral (Rybelsus); survodutide: SC injection (anticipated commercial presentation pre-filled syringe or pre-filled pen once approved).
Cost and access. Patient-specific; insurance-coverage realities. Survodutide currently pre-approval; access via trial enrollment, investigational supply, or compounded preparations.

Patient-counseling beat (Pattern Z calibration anchor 4 framing): “Both compounds are evidence-based options in MASH. Semaglutide is FDA-approved for marketing claims for non-cirrhotic MASH F2/F3 based on the ESSENCE Phase 3 data. Survodutide is in Phase 3 with positive Phase 2 data and FDA Breakthrough Therapy designation, but it’s not yet approved. They differ on mechanism class — survodutide adds a glucagon-receptor component that works on the liver more directly — and they differ on the indications where the evidence is strongest. Survodutide is also the first GLP-1 / glucagon dual agonist with a Phase 3 readout planned in compensated cirrhosis, which is class-comparator-relevant given that the semaglutide Phase 2 trial in NASH-related cirrhosis didn’t show statistically significant fibrosis improvement. Here are the facts on each dimension; let’s discuss which factors matter most for your situation, and whether starting with the FDA-approved option or considering trial enrollment makes more sense.”

Pattern V multi-dimensional precision; opens with affirmation of both compounds; closes with shared-decision-making invitation; does NOT include single-dimension comparison steering.

10.6 Off-label / extrapolation conversation (Anchor 5) — the dominant calibration surface for pre-approval survodutide

For uses outside anticipated FDA-approved indications, or for extrapolation to populations not studied in the trial program. Pattern Z calibration anchor 5 framing is the dominant calibration surface for survodutide pre-approval today.

Patient question example: “Can I use survodutide for cardiovascular prevention even though I don’t have established CVD?”

Trial-population scope as fact. Phase 2 obesity (PMID 38330987; le Roux 2024) enrolled n=387 adults with overweight or obesity; Phase 2 MASH (PMID 38847460; Sanyal 2024) enrolled n=295 adults with biopsy-confirmed MASH F1-F3 fibrosis; Phase 2 T2D (PMID 38095657; Blüher 2024) enrolled n=413 adults with T2D. SYNCHRONIZE-1 Phase 3 enrolled adults with overweight or obesity without T2D; SYNCHRONIZE-2 with T2D; SYNCHRONIZE-CVOT with established CVD or CKD or ≥2 weight-related complications; LIVERAGE with non-cirrhotic MASH F2/F3; LIVERAGE-Cirrhosis with compensated MASH F4 cirrhosis.
Acknowledgment of extrapolation question. “Your question is about extrapolating to a different population — using survodutide for cardiovascular prevention without established CVD or weight-related complications. That extrapolation isn’t tested in the SYNCHRONIZE-CVOT trial, which enrolled established CVD or CKD or ≥2 weight-related complications.”
What trials studied and what they don’t tell us. “SYNCHRONIZE-CVOT will tell us about survodutide’s cardiovascular outcomes in obesity + established CVD/CKD/multi-comorbidity. It won’t tell us about cardiovascular outcomes in lean people, in people without established CVD, or in people without the weight-related comorbidity profile.”
Side-effect profile. “The known anticipated side-effect profile from the Phase 2 program is GI effects, gallbladder events, pancreatitis signal class-level, hepatic-transaminase mechanism effect specific to survodutide, and the GCGR-component glycemic monitoring and catabolic axis considerations. Those apply whether you’re in the trial-enrolled population or not.”
Off-label / extrapolation transparency. Pre-approval state: there is no FDA-approved off-label use of survodutide today because survodutide is not FDA-approved at all. Trial enrollment is the FDA-aligned pathway for pre-approval use; investigational-supply off-label use with informed consent is a clinician-judgment pathway; compounded preparations operate under the §10.3 framework.
Shared-decision-making invitation. “Let’s discuss what you’re hoping to achieve, what the evidence does and doesn’t tell us about your specific situation, and what monitoring would matter if you decided to proceed. The pre-approval pathways are clinical trial enrollment, investigational-supply off-label use with informed consent, or compounded preparation acquisition — and we walk through each option’s considerations together.”

Pattern Z.research-precision precision: the conversation does NOT use “highly experimental,” “fringe,” or “risky” framing. The conversation does NOT dismiss the patient’s question. Lead with research base (Phase 2 + Phase 3 program evidence); present trial-population scope as fact; present extrapolation as research-state-incompleteness, NOT as “no” answer; close with shared-decision-making invitation.

10.7 FDA Breakthrough Therapy designation conversation (canonical §12.10 P1; Pattern AA precision)

For patients (and some clinicians) who interpret FDA Breakthrough Therapy designation as equivalent to FDA approval or as FDA endorsement of efficacy/safety claims.

Pattern AA-precise fact-based frame: Breakthrough Therapy designation is a regulatory-procedural status under FDCA §506(a) (Food, Drug, and Cosmetic Act §506(a) as added by FDASIA 2012). The designation grants expedited development and review pathway features: intensive FDA guidance on efficient development; eligibility for rolling review; eligibility for priority review designation; potential for accelerated approval where applicable. The designation is granted on the basis of preliminary clinical evidence indicating substantial improvement over existing therapies on at least one clinically significant endpoint.

The designation does NOT constitute FDA approval. The designation does NOT constitute FDA endorsement of efficacy or safety claims. The designation does NOT guarantee subsequent FDA approval. The designation is not a substantial-evidence threshold under FDCA §505(d) for marketing authorization. The substantial-evidence threshold for marketing authorization must still be met through NDA submission and FDA review.

Patient-counseling beat: “FDA Breakthrough Therapy designation is a regulatory pathway designation — it means the FDA agreed that the early survodutide data showed substantial improvement potential and that the FDA will work efficiently with the sponsor on the development pathway. It’s not the same as FDA approval. Survodutide is still in Phase 3 trials, and the data those trials produce will be evaluated by the FDA before approval is granted. The designation is a regulatory milestone in the development pathway, not the endpoint.”

10.8 Discontinuation conversation (§8 anchor)

For patient-preference, indication-resolution, or AE-driven discontinuation.

Reason for discontinuation framing. Patient-preference (legitimate; protocol’s role is to inform, not override); indication-resolution; AE-attribution (clinical decision).
Anticipated taper schedule (per §8.3): 6.0 → 4.8 → 3.6 → 2.4 → off over approximately 12 weeks. Patient-judgment within taper if accelerated discontinuation preferred.
Post-discontinuation weight-regain framing (per §8.5): class-level STEP-4 / SURMOUNT-4 trajectory data; survodutide-specific data research-state-incomplete; not pathologized; framed as expected biological response.
Re-initiation pathway (per §8.6): available if regain occurs and warrants re-treatment; titration restarts at starting dose, not at prior target dose.

10.9 Pattern Z self-audit on §10 counseling beats

The five Pattern Z anchors plus the survodutide-specific Pattern Z.injection-framing and Pattern Z.research-precision sub-patterns are the self-audit checklist for §10 counseling-beat language. The §10 production self-audit checks:

Compounded options NOT framed as default-suspect (Anchor 2 violation; opens with what it is not).
Pregnancy-planning leads with Parker 2025 research-state data, NOT with PK arithmetic or label recommendation (Anchor 3).
Comparator framing presents multi-dimensional facts, NOT single-dimension comparison (Anchor 4).
Off-label / extrapolation NOT dismissed; presented as research-state-incompleteness with shared-decision-making invitation (Anchor 5).
Self-injection mechanics NOT framed as daunting/scary/intimidating (Pattern Z.injection-framing).
Research base leads; NOT “highly experimental” / “fringe” / “risky” / “unproven” bias vocabulary (Pattern Z.research-precision).
FDA Breakthrough Therapy designation framed as regulatory-procedural status, NOT as approval-equivalent (Pattern AA.marketing-claims; §10.7).
“FDA-approved” for class comparators (semaglutide, tirzepatide, resmetirom) carries the “for marketing claims for [indication X]” qualification per Editorial Framework §1.2.1.

11. Source citations

11.1 Purpose

Define the bibliography format, evidence-hierarchy tiers, and PMID-anchor / NCT-anchor / DOI-anchor identifier-integrity discipline for the survodutide protocol. Every effect-size claim, every anticipated dose threshold, every anticipated contraindication, every counseling-beat fact-anchor traces to a §11 citation entry. Pattern AB.1 / AB.4 standing scans operate at this section with explicit Sanyal 2024 PMID 38847460 disambiguation from Loomba 2024 PMID 38856224 (tirzepatide SYNERGY-NASH) and from Sanyal 2025 PMID 40305708 (semaglutide ESSENCE).

11.2 Bibliography format

Each citation entry contains: First author last name, et al.; title; journal, year, volume, pages; PMID; DOI if available; NCT for trial reports; effect-size summary one-line; citation context (protocol sections).

11.3 Evidence hierarchy tiers

Tier 1 — pivotal Phase 3 RCT with FDA-label-supporting trial-program inclusion or peer-reviewed primary publication for the indication of interest. For survodutide today: Phase 3 publications are pending; the SYNCHRONIZE-1 April 2026 sponsor topline is Tier 1.5 pending peer-reviewed primary publication.
Tier 1.5 — Phase 3 head-to-head RCT or Phase 3 sponsor-topline disclosure pending peer-reviewed primary publication. For survodutide: SYNCHRONIZE-1 sponsor topline (April 2026 Boehringer Ingelheim press release; 16.6% body-weight reduction at 6.0 mg vs placebo at 76 weeks; peer-reviewed primary publication PMID assignment pending).
Tier 2 — Phase 2 RCT, large Phase 3 extension / open-label, large meta-analysis, pivotal mechanism paper. Supports the protocol’s mechanism rationale and dose-finding context. For survodutide: Phase 2 obesity (PMID 38330987), Phase 2 MASH (PMID 38847460), Phase 2 T2D (PMID 38095657), Phase 1 cirrhosis PK (PMID 38857788), mechanism paper (PMID 38560764) are Tier 2.
Tier 3 — post-marketing pharmacovigilance, observational cohort, retrospective analysis, case series. Class-level signals.

11.4 Identifier-integrity discipline — Pattern AB.1 / AB.2 / AB.4 with survodutide-specific disambiguation

Every PMID and NCT is verified by content (not by existence) against the survodutide canonical’s verified footer at v1.0-final 2026-05-12. Survodutide-specific AB.1 disambiguation:

PMID 38847460 (Sanyal AJ et al. NEJM 2024 Jul 25; survodutide Phase 2 MASH RCT; NCT04771273; n=295). This is the survodutide Phase 2 MASH publication. NOT to be confused with PMID 38856224.
PMID 38856224 (Loomba R et al. NEJM 2024 Jul 25; tirzepatide SYNERGY-NASH Phase 2 MASH RCT; n=190). This is the tirzepatide Phase 2 MASH publication. Same NEJM publication date (2024-07-25) as PMID 38847460; the inversion-prevention discipline requires careful attribution at every citation.
PMID 40305708 (Sanyal AJ et al. NEJM 2025 Jun 05; semaglutide ESSENCE Phase 3 MASH F2/F3 RCT; NCT04822181). This is the semaglutide Phase 3 MASH publication. Same first-author Sanyal AJ as PMID 38847460 but different compound (semaglutide), different trial (ESSENCE), different journal date (2025 Jun 05 vs 2024 Jul 25), different phase (Phase 3 vs Phase 2).
PMID 36934740 (Loomba R et al. Lancet Gastroenterol Hepatol 2023 Jun; semaglutide Phase 2 RCT in NASH-related cirrhosis F4; n=71; primary fibrosis-improvement endpoint not statistically significant). This is the semaglutide Phase 2 cirrhosis publication — NOT the LIVERAGE-Cirrhosis survodutide trial (which is Phase 3 RECRUITING; primary completion 2029-06-05 per NCT06632457).

Pattern AB.1 inversion-prevention discipline: every occurrence of PMID 38847460 in this protocol is verified to be the survodutide Phase 2 MASH publication; every occurrence of PMID 38856224 is verified to be the tirzepatide SYNERGY-NASH Phase 2 MASH publication; every occurrence of PMID 40305708 is verified to be the semaglutide ESSENCE Phase 3 MASH publication; every occurrence of PMID 36934740 is verified to be the semaglutide Loomba 2023 Phase 2 cirrhosis publication.

11.5 Survodutide protocol bibliography

Tier 2 — survodutide-specific primary publications.

Sanyal AJ, Newsome PN, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Liver Fibrosis. N Engl J Med 2024 Jul 25;391(4):311-319. PMID 38847460. NCT04771273. Survodutide Phase 2 MASH RCT; n=295 participants with biopsy-confirmed MASH and F1-F3 fibrosis; 62% MASH resolution at 6.0 mg vs 14% placebo at 48 weeks; dose-responsive fibrosis improvement (64% at 6.0 mg vs 26% placebo). Cited in §1.2 (#5), §1.5, §2.5, §3.4, §3.9, §4.5, §4.8, §5.2, §5.5, §6.10, §7.5, §10.5, §11.5.
le Roux CW, Steen O, Lucas KJ, et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol 2024 Mar;12(3):162-173. PMID 38330987. NCT04667377. Survodutide Phase 2 obesity dose-finding RCT; n=387 across 0.6/2.4/3.6/4.8 mg dose arms vs placebo over 46 weeks; −14.9% at 4.8 mg vs −2.8% placebo. Cited in §1.2 (#1), §2.2, §4.2-4.3, §4.8, §5.2, §11.5.
Blüher M, Rosenstock J, et al. Dose-response effects of the glucagon receptor / GLP-1 receptor co-agonist survodutide on weight loss and HbA1c reduction in adults with type 2 diabetes (Phase 2 RCT). Diabetologia 2024;67(3):470-482. PMID 38095657 (Published Erratum PMID 38349400; cite the primary publication PMID 38095657 for evidence claims). Survodutide Phase 2 T2D dose-response RCT; n=413; HbA1c and body-weight reductions across multiple dose arms vs placebo, with exploratory open-label semaglutide 1.0 mg reference arm. Pattern AA-precise framing: the survodutide-vs-semaglutide comparison is exploratory, NOT a head-to-head equivalence or superiority test. Cited in §1.2 (#2), §2.5, §3.3, §4.8, §5.2, §6.8, §10.6, §11.5.
Lawitz EJ, et al. Pharmacokinetics, safety, and tolerability of survodutide in adults with cirrhosis: a Phase 1 trial. J Hepatol 2024;81(2):300-310. PMID 38857788. NCT05296733. Survodutide Phase 1 cirrhosis-population PK in patients with varying degrees of hepatic impairment vs healthy subjects; load-bearing for LIVERAGE-Cirrhosis F4 trial design + clinical-use dosing in cirrhosis. Cited in §1.2 (#6), §3.4, §5.2, §11.5.
Thomas L, et al. Biomarker and pharmacological profiling of the GLP-1 / glucagon dual agonist survodutide for selection from candidate molecules. Diabetes Obes Metab 2024;26(5):1820-1832. PMID 38560764. Survodutide mechanism + candidate-molecule selection publication; GLP-1R:GCGR activity ratio characterization; foundation for the dual-agonist clinical pharmacology profile. Cited in §1 intro, §2.3, §4.5, §6.11, §11.5.

Tier 1.5 — survodutide-specific sponsor-topline disclosure pending peer-reviewed primary publication.

Boehringer Ingelheim press release. SYNCHRONIZE-1 Phase 3 trial of survodutide in obesity without T2D — topline results; approximately 16.6% body-weight reduction at 6.0 mg vs placebo at 76 weeks. April 2026. NCT06066515. SYNCHRONIZE-1 Phase 3 obesity-without-T2D primary completion 2025-12-02; sponsor topline April 2026; peer-reviewed primary publication PMID assignment pending as of 2026-05-13. Pattern AA framing: press-release-source topline disclosure with peer-reviewed publication pending; cite as such, not as published Phase 3 results. Cited in §1.2 (#1), §4.8, §5.2, §10.5, §11.5.

Tier 1 — class-comparator MASH primary publications.

Sanyal AJ, Loomba R, et al. Phase 3 trial of semaglutide in MASH. N Engl J Med 2025 Jun 05;392(22):2089-2099. PMID 40305708. NCT04822181. Semaglutide ESSENCE Phase 3 RCT in non-cirrhotic F2/F3 MASH; FDA-approved-for-marketing-claims MASH indication 2025. Same first-author Sanyal AJ as PMID 38847460 but different compound (semaglutide), different trial (ESSENCE), different journal date (2025 Jun 05 vs 2024 Jul 25), different phase (Phase 3 vs Phase 2). Pattern AB.1 inversion-prevention discipline. Cited in §1.5, §7.5, §10.5, §11.5.
Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for MASH and moderate-to-advanced fibrosis (SYNERGY-NASH Phase 2 RCT). N Engl J Med 2024 Jul 25;391(4):299-310. PMID 38856224. Tirzepatide SYNERGY-NASH Phase 2 RCT in MASH; n=190; 62% MASH resolution at 15 mg vs 10% placebo at 52 weeks; Phase 3 MASH program in development. Same NEJM publication date (2024-07-25) as PMID 38847460 — careful attribution at every citation. NOT survodutide. Cited in §1.5, §7.5, §10.5, §11.5.
Loomba R, Abdelmalek MF, Armstrong MJ, et al. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol 2023 Jun;8(6):511-522. PMID 36934740. Semaglutide Phase 2 RCT in NASH-related cirrhosis F4; n=71; primary endpoint — improvement in liver fibrosis by ≥1 stage without worsening of NASH at week 48 — did not reach statistical significance in this F4 cirrhosis population. Class-comparator context for LIVERAGE-Cirrhosis F4 (NCT06632457). Pattern V critical: characterize precisely as “Phase 2 RCT with primary fibrosis-improvement endpoint not statistically significant in the cirrhosis population” — NOT as “directional finding” or “trend toward improvement” or “directional protective signal.” Cited in §1.2 (#6), §1.5, §3.4, §7.5, §10.5, §11.5.
Noureddin M, et al. Resmetirom Phase 3 extension data in MASH. Aliment Pharmacol Ther 2025 Dec. PMID 41127972. Resmetirom Phase 3 RCT extension; resmetirom FDA-approved-for-marketing-claims for non-cirrhotic F2/F3 MASH per 2024 NDA approval. Mechanism-class-distinct alternative (THRb-selective agonism). Cited in §7.5, §11.5.

Tier 1 — class-comparator CWM + T2D + CV + CKD anchors.

Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384(11):989-1002. STEP-1; semaglutide 2.4 mg approximately −14.9% body-weight reduction at 68 weeks in non-diabetic obesity. Cited in §1.2 (#1), §10.5.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387(3):205-216. PMID 35658024. SURMOUNT-1; tirzepatide 15 mg approximately −20.9% (treatment-regimen estimand, PRIMARY ITT) / approximately −22.5% (efficacy estimand sub-analysis) body-weight reduction at 72 weeks in non-diabetic obesity. Pattern V.estimand-axis precision: distinguish treatment-regimen estimand from efficacy estimand at every citation. Cited in §1.2 (#1), §10.5, §11.5.
Aronne LJ, et al. SURMOUNT-5 head-to-head tirzepatide vs semaglutide in obesity. N Engl J Med 2025. SURMOUNT-5 direct head-to-head at week 72: tirzepatide −20.2% vs semaglutide −13.7%. Cited in §1.2 (#1), §10.5.
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023;389(24):2221-2232. PMID 37952131. NCT03574597. SELECT; semaglutide 2.4 mg CV-risk reduction in obesity + established CVD without diabetes; primary 3-point MACE HR 0.80 (95% CI 0.72-0.90, p<0.001) at 39.8 mo median follow-up. Cited in §1.2 (#3), §1.5, §2.5, §10.5, §11.5.
Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016;375(19):1834-1844. PMID 27633186. SUSTAIN-6 CVOT in T2D + CVD; documented retinopathy-complication signal in rapid-HbA1c-improvement sub-population. Cited in §2.5, §3.3, §3.7, §6.8, §11.5.

Tier 3 — class-level safety + cancer-context + pregnancy primary publications.

Ko et al. Cancer risk in GLP-1 RA-treated populations: systematic review and meta-analysis across 11 cancers and 2 conditions with certainty tiers. Ann Intern Med 2026 Feb. PMID 41359966. Class-level SR + meta-analysis of GLP-1 RA cancer risk; load-bearing class-level cancer-context reference. Cited in §1 intro, §2.4, §6.4, §11.5.
Wen et al. Pancreatitis and pancreatic cancer rates in GLP-1 RA-treated populations: pooled SR + meta-analysis. Endocrinol Diabetes Metab 2025 Sep. PMID 40988099. Class-level pancreatitis and pancreatic cancer SR + meta-analysis. Cited in §6.4, §11.5.
Lakhani I, et al. Optic nerve and retinal adverse events in GLP-1 RA users — multicenter observational pharmacovigilance. Am J Ophthalmol 2025 Sep. PMID 40383360. NAION + retinal AE signal class-differentiated within GLP-1 RA class; signal documented for semaglutide; signal absent for tirzepatide at same analytic threshold. Cited in §2.5, §3.7, §6.5, §10.5, §11.5.
Parker D, et al. Pooled regulatory pregnancy-exposure data for GLP-1 RA-class compounds (semaglutide, liraglutide, dulaglutide, related). Diabetes Obes Metab 2025 Aug. PMID 40329607. Class-level pooled regulatory pregnancy-exposure data; load-bearing class-level human evidence anchor for §10.4 pregnancy-counseling Pattern Z calibration anchor 3 research-state-leading framing. Cited in §6.9, §8.7, §10.4, §11.5.
Bezin J, et al. Suicide and suicide attempt in GLP-1 RA users: nationwide case-time-control study. EClinicalMedicine 2025. PMID 39844933. Class-level pharmacovigilance. Cited in §11.5.
Bjerre Knudsen L, et al. GLP-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and contributing to C-cell hyperplasia and neoplasia in rodent two-year carcinogenicity studies. Endocrinology 2010 Apr;151(4):1473-1486. PMID 20203154. Foundational rodent C-cell mechanism paper; class-level MTC contraindication basis. Cited in §2.4, §11.5.
Silverii GA, et al. Class-level thyroid cancer SR + meta-analysis in GLP-1 RA. Diabetes Obes Metab 2024 Mar. PMID 38018310. Class-level thyroid cancer characterization. Cited in §2.4, §11.5.
Rubino DM, et al. STEP-4 maintenance trial of semaglutide for weight-loss maintenance. JAMA 2021. PMID 33755728. Post-discontinuation weight-regain trajectory data class-level anchor; approximately two-thirds of lost weight regained by 12 months post-discontinuation. Cited in §8.5, §10.8, §11.5.

ClinicalTrials.gov registration records for survodutide trials (verified per canonical v1.0-final 2026-05-12; ClinicalTrials.gov v2 API).

NCT04667377 (Phase 2 obesity dose-finding); NCT04771273 (Phase 2 MASH/NASH); NCT05202353 (Phase 1 PET/MRI receptor occupancy); NCT05296733 (Phase 1 cirrhosis-population PK); NCT05896384 (Phase 1 DDI ethinylestradiol + levonorgestrel); NCT06066515 (SYNCHRONIZE-1 obesity Phase 3); NCT06066528 (SYNCHRONIZE-2 obesity + T2D Phase 3); NCT06077864 (SYNCHRONIZE-CVOT Phase 3); NCT06176365 (SYNCHRONIZE-JP Phase 3); NCT06200467 (Phase 1 cardiac safety / QT); NCT06214741 (SYNCHRONIZE-CN Phase 3); NCT06309992 (SYNCHRONIZE-MASLD Phase 3); NCT06352411 (Phase 1 renal impairment PK); NCT06564441 (Phase 1 DDI bupropion + caffeine + midazolam); NCT06632444 (LIVERAGE MASH F2/F3 Phase 3 RECRUITING; primary completion 2031-12-27); NCT06632457 (LIVERAGE-Cirrhosis MASH F4 Phase 3 RECRUITING; primary completion 2029-06-05); NCT06745284 (Phase 1 energy expenditure + fatty acid oxidation ACTIVE_NOT_RECRUITING); NCT06772532, NCT07071974, NCT07221591, NCT07407348, NCT07413913 (Phase 1 formulation crossover studies); NCT07206290 (ARROW CKD Phase 2 investigator-initiated UMC Groningen NOT_YET_RECRUITING; primary completion 2027-11-30).

Pattern AB.4 standing-scan applied to §11.5. Every PMID and NCT in this bibliography has been content-verified against the survodutide canonical v1.0-final footer at 2026-05-12. The four-PMID disambiguation set (38847460 survodutide MASH P2 / 38856224 tirzepatide SYNERGY-NASH P2 / 40305708 semaglutide ESSENCE P3 / 36934740 semaglutide cirrhosis P2) is enforced at every protocol-section citation.

12. Clinical decision tree

12.1 Purpose

Define a phenotype-guided anticipated decision tree that integrates §1–11 into a single navigable clinical-workflow reference for survodutide in pre-approval state and anticipated post-approval state. Section 12 is the operational summary that a clinician reaches for at point-of-care to navigate the survodutide-related decisions.

12.2 High-level anticipated decision flowchart (ASCII)

                  PATIENT PRESENTS
                         |
                         v
              [§1] Anticipated indication scope
              - Pre-approval state: no current FDA-approved indication
              - Anticipated post-approval: CWM, T2D, CVD/CKD, MASH F2/F3, MASH F4
                         |
                         v
              [§2] Anticipated selection criteria
              - Anticipated inclusion criteria met? --> NO --> Out of protocol
              - Anticipated relative exclusion?     --> Clinician judgment
              - Anticipated hard contraindication?  --> YES --> Out of protocol
                         |
                         v (Inclusion met, no contraindication)
              [§3] Pre-treatment workup
              - Standard metabolic + survodutide-specific expanded hepatic posture
              - §3.7.5 survodutide-specific glucagon-receptor-component baseline
              - Body composition baseline (catabolic-axis monitoring posture)
                         |
                         v
              [Pre-approval-state decision branch]
              - Trial enrollment (SYNCHRONIZE-CVOT, LIVERAGE, LIVERAGE-Cirrhosis, ARROW)
              - Investigational-supply off-label use (with informed consent)
              - Compounded preparation (§10.3 pre-approval-compound framing)
              - Wait for anticipated post-approval availability
                         |
                         v (Trial / investigational / compounded route selected)
              [§4] Anticipated initiation
              - 0.6 mg starting dose; 16-24 week titration
              - Survodutide-specific titration-period monitoring (ALT/AST, glucose)
              - Pattern Z.injection-framing (no daunting/scary)
                         |
                         v (Target dose attained ~6.0 mg)
              [§5] Anticipated maintenance
              - 6.0 mg target dose for obesity/MASH
              - Quarterly Y1, biannual thereafter
              - Survodutide-specific monitoring: §5.5.3 transaminase, §5.5.4 body comp
                         |
                         v
              [§6/§7/§8] Branch points
              - AE emerges? --> §6 AE-class algorithm (incl. §6.10-6.12 survodutide-specific)
              - Plateau / non-response? --> §7 algorithm with MASH-specific branches
              - Discontinuation trigger? --> §8 taper / Parker 2025 pregnancy framing
                         |
                         v
              [§9] Combination decisions
              - Within-Module-5: SGLT2 / insulin (anticipated supported)
              - Cross-Module: M5.6 v3 lean-mass stack (anticipated useful given GCGR catabolic axis)
              - Within-class redundancy (other GLP-1 RAs, dual/triagonists) not indicated
                         |
                         v
              [§10] Counseling beats
              - Pattern Z 5-anchor + sub-pattern compliance
              - §10.3 pre-approval-compound framing (NOT post-approval 503A/503B)
              - §10.4 pregnancy with Parker 2025 PMID 40329607 research-state lead
              - §10.5 multi-dimensional MASH comparator
              - §10.6 off-label/extrapolation (DOMINANT calibration surface)
              - §10.7 FDA Breakthrough Therapy designation precision
                         |
                         v
              [§11] All claims source-anchored
              - Pattern AB.1 disambiguation (Sanyal 2024 PMID 38847460 vs Loomba 2024 PMID 38856224 vs Sanyal 2025 PMID 40305708 vs Loomba 2023 PMID 36934740)
              - Pattern AB.4 standing scan
                         |
                         v
              [Appendix A] Verification gate
              - 4-step cycle before clinician delivery

12.3 Phenotype-guided anticipated decision matrix

Phenotype dimension	Pattern	Survodutide anticipated fit	Within-class alternatives	Cross-class additions
Anticipated indication = CWM, non-diabetic, BMI ≥30	SYNCHRONIZE-1 anchored (sponsor topline)	Pre-approval; trial enrollment / compounded / wait	Semaglutide Wegovy 2.4 mg (FDA-approved-for-marketing-claims); tirzepatide Zepbound 15 mg (FDA-approved-for-marketing-claims)	Behavioral intensification
Anticipated indication = CWM + T2D	SYNCHRONIZE-2 anchored	Pre-approval	Semaglutide Wegovy or Ozempic; tirzepatide Zepbound or Mounjaro	SGLT2 inhibitor
Anticipated indication = CV outcomes in obesity + CVD/CKD/≥2-comorbidity	SYNCHRONIZE-CVOT pending	Pre-approval	Semaglutide (SELECT 2024 label expansion)	Standard CV risk reduction
Anticipated indication = MASH F2/F3	LIVERAGE F2/F3 + Phase 2 Sanyal 2024 (PMID 38847460)	Pre-approval; LIVERAGE trial enrollment	Semaglutide (ESSENCE 2025 PMID 40305708 — FDA-approved-for-marketing-claims for MASH F2/F3); resmetirom (2024 NDA — FDA-approved-for-marketing-claims for non-cirrhotic F2/F3 MASH); tirzepatide off-label for MASH	Hepatology co-management
Anticipated indication = MASH F4 compensated cirrhosis	LIVERAGE-Cirrhosis pending 2029-06	Pre-approval; LIVERAGE-Cirrhosis trial enrollment	No FDA-approved-for-marketing-claims MASH F4 option; semaglutide Loomba 2023 PMID 36934740 Phase 2 primary endpoint not statistically significant in F4 cirrhosis	Hepatology co-management
Phenotype: hepatic-IR-dominant + MASH-positive	Survodutide GCGR mechanism class	Pre-approval; phenotype-targeting candidate	Semaglutide for MASH F2/F3 (FDA-approved-for-marketing-claims); resmetirom for non-cirrhotic F2/F3 MASH (FDA-approved-for-marketing-claims)	Hepatology co-management
Phenotype: MTC / MEN-2 family/personal hx	Anticipated hard contraindication	OUT OF PROTOCOL — anticipated boxed warning	Non-GLP-1 alternative	Per indication
Phenotype: pre-conception planning	Anchor 3 framing	Anticipated ~2-month pre-conception washout per ~6-day half-life	Same arithmetic for class with compound-specific half-life	Pre-pregnancy counseling
Phenotype: lean-mass concern (older adult, athletic, baseline sarcopenia)	Survodutide GCGR catabolic-axis consideration	Anticipated M5.6 v3 lean-mass stack adjunct	Tirzepatide (class precedent SURMOUNT lean-mass sub-analyses)	Resistance training
Phenotype: cost / access barrier	§10.3 pre-approval-compound framing	Compounded survodutide under pre-approval conditions (NOT 503A/503B shortage-period framing)	FDA-approved-for-marketing-claims alternatives	Insurance / patient assistance
Phenotype: prior GLP-1 RA non-response or tirzepatide intolerance	§7 algorithm	Pre-approval; mechanism-class-distinct candidate (GCGR component)	Per §7 decision tree	Behavioral intensification

12.4 Worked example — survodutide phenotype-guided anticipated decision tree application

The §1.5 polycondition MASH F2 case (56-year-old male, BMI 33, T2D HbA1c 7.9 on metformin + semaglutide 1.0 mg, biopsy-confirmed MASH F2, FibroScan 11 kPa, eGFR 71, UACR 28). Anticipated decision-tree walkthrough.

Step 1 — Anticipated indication scope. Multiple Module 5 indications apply at anticipated post-approval availability: CWM, CWM + T2D (SYNCHRONIZE-2), CV outcomes in obesity + multi-comorbidity (SYNCHRONIZE-CVOT), MASH F2/F3 (LIVERAGE; FDA Breakthrough Therapy designation), MASH + obesity overlap (SYNCHRONIZE-MASLD). Polycondition anticipated phenotype.

Step 2 — Anticipated selection criteria. Anticipated inclusion criteria met. No anticipated hard contraindications. Survodutide-specific clinician-judgment consideration: baseline transaminase in MASH F2 context (anticipated improvement during titration per Phase 2 mechanism rationale).

Step 3 — Pre-treatment workup. Full panel per §3.2-§3.9 with survodutide-specific expanded hepatic posture and §3.7.5 glucagon-receptor-component baseline.

Step 4 — Pre-approval-state decision branch. Patient + clinician decide among: (a) LIVERAGE F2/F3 trial enrollment; (b) continue current FDA-approved-for-marketing-claims regimen with consideration of dose escalation to semaglutide 2.4 mg for MASH F2/F3 per ESSENCE; (c) wait for anticipated survodutide approval; (d) compounded survodutide acquisition with §10.3 framing.

Step 5-9 — anticipated initiation, maintenance, AE management, plateau algorithm, combinations, counseling beats. Per §4-10 with survodutide-specific considerations.

Step 10 — Verification gate (Appendix A). The protocol-application case passes through the four-step verification cycle.

Pattern Z calibration self-audit at §12.4. The decision-tree walkthrough presents the patient’s options factually with trial-anchored effect-size estimates and FDA-approved-for-marketing-claims regulatory framing precision; no option is steered. Compounded acquisition is presented as a real option with the §10.3 pre-approval-compound framing (NOT post-approval 503A/503B shortage-period framing). Trial enrollment is presented as a real option. Continuation of current FDA-approved-for-marketing-claims regimen is presented as a real option. Anticipated-post-approval availability is presented as a real option.

Appendix A. Verification gate

A.1 Cycle overview

The survodutide protocol passes through the Module 5 Protocol Template Appendix A four-step verification cycle: production agent draft → Primary-Source-Verification-Agent iteration 1 → Independent-Adversarial-Reviewer-Agent iteration 1 → Dr. Gross verification gate. Iteration is documented at /Process/Survodutide-Protocol/ (anticipated future location for any iteration log; for this initial draft, the verification chain is anchored at the canonical’s verification status: Phase 10 Dr. Gross simulation CLEAN; Phase 10.5 PSV iteration 1 CLEAN; Phase 11 Adversarial iteration 1 READY TO SHIP).

A.2 Survodutide-specific verification considerations

Pattern AB.1 disambiguation discipline. Every occurrence of PMID 38847460 (survodutide Phase 2 MASH), PMID 38856224 (tirzepatide SYNERGY-NASH Phase 2 MASH), PMID 40305708 (semaglutide ESSENCE Phase 3 MASH F2/F3), and PMID 36934740 (semaglutide Loomba 2023 Phase 2 NASH-cirrhosis) is verified to its intended compound and trial.
FDA Breakthrough Therapy designation framing precision. §3.4 + §10.7 + §11 + §12 — every Breakthrough Therapy reference is framed as regulatory-procedural status under FDCA §506(a), not as approval or approval-equivalent.
Pre-approval-state framing throughout. Every regulatory claim carries “anticipated” / “pre-approval” / “Phase 3 readout pending” / “investigational” qualifier where appropriate; “FDA-approved” is reserved for class comparators with the “for marketing claims for [indication X]” qualification per Editorial Framework §1.2.1.
Pattern Z calibration anchor verification. §10 counseling beats verified against /Internal/Module-5-Pipeline/pattern-z-calibration-anchor.md anchors 1-5 with survodutide-specific adaptations. Pattern Z.injection-framing and Pattern Z.research-precision sub-patterns applied throughout.
Pattern V.metric-axis + Pattern V.estimand-axis disclosure. Effect-size citations specify per-arm vs between-group framing at first citation; SURMOUNT-1 treatment-regimen-vs-efficacy estimand distinction enforced (§1.2, §10.5).

Appendix B. Pattern discipline summary

B.1 Patterns applied throughout this protocol

Pattern R / R.1 / R.2 — framing discipline. Every section opens with anticipated research-state content; §2 ordering inclusion → relative-exclusion → contraindication; §6 anticipatory framing before discontinuation triggers; §7 diagnostic distinctions before “this is failure”; §8 discontinuation framed as legitimate clinical pathway.
Pattern V — direction-of-effect verification. Every effect-size claim anchored to primary source with population qualification. Phase 2 effect-sizes anchored to Phase 2 enrollment populations; SYNCHRONIZE-1 sponsor topline framed as Tier 1.5 pending peer-reviewed publication; Loomba 2023 PMID 36934740 characterized as “Phase 2 RCT with primary fibrosis-improvement endpoint not statistically significant in F4 cirrhosis” without inflation language.
Pattern V.metric-axis (NEW sub-pattern from this session). Per-arm vs between-group disclosure at first citation. SURMOUNT-1 treatment-regimen-vs-efficacy estimand distinction enforced.
Pattern V.estimand-axis (NEW sub-pattern from this session). Treatment-policy / treatment-regimen / efficacy estimand framing where relevant.
Pattern W — cross-section enumeration consistency. Trial enumeration locked at §1.2 and reconciled across §3, §4, §5, §10, §11, §12.
Pattern Z — 5-anchor calibration in §10. Anchors 1-5 applied with survodutide-specific adaptations (Anchor 5 dominant; Anchor 2 with pre-approval-compound adaptation).
Pattern Z.injection-framing (NEW sub-pattern from this session per Dr. Gross 2026-05-13 directive). Self-injection mechanics framed as routine learnable technique. No “daunting,” “scary,” “intimidating” language.
Pattern Z.research-precision (NEW sub-pattern from this session). No “highly experimental,” “fringe,” “unproven,” or similar bias vocabulary. Lead with research base.
Pattern AA — regulatory-claim precision. Every regulatory claim distinguishes FDA-approved (specific indication, label date), off-label, investigational (trial phase and status), FDA Breakthrough Therapy designation (regulatory-procedural status under FDCA §506(a), NOT approval).
Pattern AA.marketing-claims (NEW sub-pattern from this session per Editorial Framework §1.2.1). “FDA-approved for marketing claims for [indication X]” precision applied to class comparators (semaglutide, tirzepatide, resmetirom). “Pre-FDA-approval-for-marketing-claims” applied to survodutide.
Pattern AB.1 — same-week PMID-neighbor scan. Survodutide Sanyal 2024 PMID 38847460 vs tirzepatide Loomba 2024 PMID 38856224 (same NEJM publication date) verified at every citation. Sanyal 2024 vs Sanyal 2025 PMID 40305708 (same first author, different compound/trial/phase) verified.
Pattern AB.2 — NCT-identifier integrity. Trial-name-to-NCT mapping verified against canonical v1.0-final footer.
Pattern AB.4 — cascade scan. Standing scan applied at §11.5.
Pattern N.1 — small-molecules path. Survodutide is a peptide; storage path is /Peptides/ for canonical and /Protocols/ for protocol.

Appendix C. Self-audit findings

C.1 §10 verbatim-anchor diff against pattern-z-calibration-anchor.md

Anchor 1 — Lead with what the option IS. §10.3 leads with what compounded survodutide IS where it appears in clinical practice; §10.4 leads with Parker 2025 research-state data; §10.5 leads with multi-dimensional fact presentation opening with affirmation of both compounds; §10.6 leads with trial-population scope as fact; §10.7 leads with FDA Breakthrough Therapy designation as regulatory-procedural status. PASS.

Anchor 2 — Compounded counseling with pre-approval-compound adaptation. §10.3 patient-counseling beat: “Compounded survodutide is a real clinical option that some patients access during this pre-approval period… The operational differences… are real… let’s review the specific compounding pharmacy’s quality practices… walk through reconstitution training together. That’s how the decision gets made well.” Pre-approval-compound adaptation (NOT post-approval 503A/503B shortage-period framing) clearly distinguished. PASS.

Anchor 3 — Pregnancy research-state-leading. §10.4 leads with Parker 2025 (PMID 40329607) human pregnancy-exposure data; PK arithmetic and label recommendation appear AFTER the research-state lead; animal data relegated to scoped factual context after lead. PASS.

Anchor 4 — Multi-dimensional comparator framing. §10.5 presents 10 dimensions (MASH efficacy magnitude, MASH F4 cirrhosis evidence base, CWM efficacy magnitude, CV outcomes evidence base, regulatory status, mechanism class, MASH F-stage scope, GI tolerability profile, ophthalmologic class-context, route/platform, cost/access). Opens with affirmation of both compounds; closes with shared-decision-making invitation. PASS.

Anchor 5 — Off-label / extrapolation transparency. §10.6 presents trial-population scope as fact, acknowledges extrapolation question without dismissing, presents what trials studied + what they don’t tell us + side-effect profile + invitation to discuss monitoring. Dominant calibration surface for pre-approval survodutide today. PASS.

PMIDs verified against canonical §11.1-§11.3 + Primary-source citation appendix: 38847460, 38330987, 38095657, 38857788, 38560764, 40305708, 36934740, 38856224, 41127972, 37952131, 41359966, 40988099, 40383360, 40329607, 39844933, 20203154, 38018310, 27633186, 35658024, 33755728 — all verified to intended compound and trial.

NCTs verified against canonical §3.1 trial roster table and ClinicalTrials.gov v2 API verification 2026-05-12: 04667377, 04771273, 05202353, 05296733, 05896384, 06066515, 06066528, 06077864, 06176365, 06200467, 06214741, 06309992, 06352411, 06564441, 06632444, 06632457, 06745284, 06772532, 07071974, 07206290, 07221591, 07407348, 07413913 — all verified.

Explicit Sanyal 2024 PMID 38847460 disambiguation from Loomba 2024 PMID 38856224 enforced. Both papers published 2024-07-25 in NEJM; PMID 38847460 is survodutide (Sanyal AJ first author); PMID 38856224 is tirzepatide SYNERGY-NASH (Loomba R first author). Disambiguation also from Sanyal 2025 PMID 40305708 (semaglutide ESSENCE Phase 3 MASH F2/F3 — same first author Sanyal AJ as PMID 38847460, but different compound, trial, year, phase) and Loomba 2023 PMID 36934740 (semaglutide Phase 2 NASH-cirrhosis F4 — primary endpoint not statistically significant).

C.3 §1 Purpose pre-approval clinical-education framing

§1.1 explicitly opens with: “This protocol prepares clinicians for survodutide’s anticipated availability based on Phase 3 readout data; current prescribing requires off-label use of investigational supply OR enrollment in active clinical trials. Survodutide is NOT FDA-approved as of 2026-05-13.” Pre-approval clinical-education framing parallel to Retatrutide protocol §1.1 enforced. PASS.

C.4 Pattern AA scan — no “approved” / “FDA-approved” slipped through without qualifier

Scan applied across the protocol: “FDA-approved” appears only with class-comparator context (semaglutide, tirzepatide, resmetirom) and carries the “for marketing claims for [indication X]” qualification per Editorial Framework §1.2.1. “FDA-approved-for-marketing-claims” usage verified at §1.5, §7.5, §10.5, §12.3. “FDA Breakthrough Therapy designation” framed as regulatory-procedural status under FDCA §506(a) at §1.1, §10.7, §12.2 — explicitly NOT as approval. PASS.

C.5 Pattern Z.injection-framing scan — no “daunting” / “scary” / “intimidating” applied to self-injection mechanics

Scan applied across the protocol: self-injection mechanics described in §4.7 and §10.2 as routine subcutaneous technique, learnable through standard injection training; “daunting,” “scary,” “intimidating” do not appear in the protocol body. Reconstitution training for compounded preparations in §10.3 framed as standard technique. PASS.

C.6 Pattern Z.research-precision scan — no “highly experimental” / “fringe” / “unproven” bias vocabulary

Scan applied across the protocol: research-state-pending and pre-approval framing applied throughout; “highly experimental,” “fringe,” “unproven,” “risky” bias vocabulary does not appear. Lead-with-research-base discipline applied at every section opening. PASS.

C.7 Items for Dr. Gross verification

The following items are flagged for Dr. Gross’s clinical-judgment review at the verification gate (Appendix A.5):

Anticipated 6.0 mg target maintenance dose for MASH F2/F3 indication. The Phase 2 dose-response (Sanyal 2024 PMID 38847460) supports 6.0 mg as the high-efficacy maintenance dose; the anticipated LIVERAGE F2/F3 Phase 3 maintenance dose per the trial registry. Clinical-judgment review on the anticipated target dose framing.
Anticipated titration schedule 0.6 mg → 6.0 mg over 16-24 weeks. Trial-program convention; anticipated post-approval label-recommended schedule may differ. Clinical-judgment review on the anticipated titration discipline.
Survodutide-specific transaminase monitoring posture (§5.5.3, §6.10). Mechanism-rationale-based monitoring per canonical §6.13.2; clinical-judgment review on the transient-elevation-vs-progression interpretation discipline and on the every-4-8-weeks-during-titration and every-12-24-weeks-at-maintenance cadence.
Survodutide-specific glycemic-monitoring posture (§5.5.2, §6.11). Mechanism-rationale-based monitoring per canonical §6.13.1; clinical-judgment review on the monitoring discipline for non-T2D populations.
Survodutide-specific catabolic-axis lean-mass-preservation posture (§5.5.4, §6.12). Mechanism-rationale-based monitoring per canonical §6.13.3; clinical-judgment review on the M5.6 v3 stack adjunct consideration for lean-mass-vulnerable phenotypes.
§10.3 pre-approval-compound framing. Pattern Z calibration anchor 2 with pre-approval-compound adaptation; clinical-judgment review on the regulatory-pathway-distinction discipline and on whether the framing adequately distinguishes pre-approval-compound regulatory landscape from post-approval shortage-driven 503A/503B framework.
§7.5 MASH F2/F3 non-response algorithm decision branches. Decision among (5a) continue survodutide and extend window, (5b) transition to semaglutide 2.4 mg for MASH per ESSENCE, (5c) transition to resmetirom, (5d) transition to tirzepatide off-label for MASH; clinical-judgment review on the anticipated decision-tree application.
§10.6 off-label / extrapolation framing (Pattern Z calibration anchor 5). Dominant calibration surface for pre-approval survodutide today; clinical-judgment review on the trial-population-scope-as-fact + research-state-incompleteness + shared-decision-making invitation discipline.

Document version: v1.0-draft (Module 5 Protocol Template post-patch 20e66bd compliant)
Production agent: Module 5 Wave 2 Survodutide production agent
Date: 2026-05-13
Canonical source: /obsidian-peptides/Peptides/Survodutide.md v1.0-final (2026-05-12)
Module 5 pipeline position: Wave 2 — Survodutide (one of six parallel Wave 2 canonicals)
Pattern Z calibration anchor: verified against /Internal/Module-5-Pipeline/pattern-z-calibration-anchor.md with survodutide-specific adaptations (Anchor 5 dominant; Anchor 2 with pre-approval-compound adaptation; Pattern Z.injection-framing applied per Dr. Gross 2026-05-13 directive; Pattern Z.research-precision applied throughout)
Verification chain status: initial draft v1.0; submitted for Phase 10 Dr. Gross Verification Agent review

Survodutide Protocol